Fungicidal 3-{phenyl[(heterocyclylmethoxy)imino]methyl}-oxadiazolone derivatives

ABSTRACT

The present invention provides 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives of formula (I) 
                         
Wherein A, X 1  to X 3 , Y 1  to Y 5  represent various substituents.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a §371 National Stage Application of PCT/EP2014/054026, filed 3 Mar. 2014, which claims priority to EP 133356004.5 filed 4 Mar. 2013 and U.S. 61/803,277, filed 19 Mar. 2013.

BACKGROUND

1. Field of the Invention

The present invention relates to 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivatives, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

2. Description of Related Art

In European patent application no. 1184382, there are disclosed certain heterocyclyloxime derivatives of the following chemical structure:

that are excluded from the scope of the present invention.

In world patent application WO2009/130193, there are disclosed certain hydroximoyl-heterocycles derivatives of the following chemical structure:

Q is a phenyl ring, L1 a methylene linker and A an heterocycle. Said compounds are not part of the scope of the present invention.

It is always of high-interest in agriculture to use novel pesticide compounds in order to avoid or to control the development of resistant strains to the active ingredients. It is also of high-interest to use novel compounds being more active than those already known, with the aim of decreasing the amounts of active compound to be used, whilst at the same time maintaining effectiveness at least equivalent to the already known compounds. We have now found a new family of compounds which possess the above mentioned effects or advantages.

SUMMARY

Accordingly, the present invention provides 3-{phenyl[(heterocyclylmethoxy)imino]methyl}-oxadiazolinone derivatives of formula (I)

wherein

-   -   X¹ represents a hydrogen atom, a formyl group, substituted or         non-substituted C₁-C₈-alkyl, substituted or non-substituted         C₃-C₈-cycloalkyl, a substituted or non-substituted         C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl,         substituted or non-substituted C₁-C₈-alkylcarbonyl;     -   X² and X³ independently represents O or C═O, provided that X²         represents O when X³ is C═O and X² represents C═O when X³ is O     -   A is selected in the list consisting of A¹ to A²:

wherein

Z¹ represents a hydroxy group, a sulfenyl group, a formyl group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a formyloxy group, a carbamoyl group, a N-hydroxycarbamoyl group, sulfenylthioylamino, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted (C₁-C₈-alkylamino)-amino group, substituted or non-substituted N—C₁-C₈-alkyl-(C₁-C₈-alkylamino)-amino group, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted aryl-C₂-C₈-alkynyl, substituted or non-substituted C₃-C₈-cycloalkyl-C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted C₁-C₈-alkylcarbonyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N,N′-di-C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbamoyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N,N′-di-C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N,N′-di-C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamothioyl, substituted or non-substituted C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted (C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted substituted or non-substituted (di-C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₁-C₈-halogenoalkylsulfenyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted C₁-C₈-alkylaminosulfamoyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted C₁-C₈-alkylsulfenylamino, substituted or non-substituted C₁-C₈-alkylsulfonylamino, substituted or non-substituted C₁-C₈-alkoxysulfonylamino, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted (C₁-C₆-alkylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkenylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkynylideneamino)oxy, substituted or non-substituted (benzylideneamino)oxy, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino;

-   -   Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen         atom, substituted or non-substituted C₁-C₈-alkyl, substituted or         non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted         C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl,         substituted or non-substituted C₁-C₈-alkoxy;     -   Y¹ to Y⁵ independently represent a hydrogen atom, a halogen         atom, a nitro group, a cyano group, a substituted or         non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a         pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted         C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl,         substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5         halogen atoms, a C₂-C₈-alkenyl, substituted or non-substituted         C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy,         substituted or non-substituted C₁-C₈-halogenoalkoxy having 1 to         5 halogen atoms, substituted or non-substituted         C₁-C₈-alkylsulfenyl, substituted or non-substituted         C₂-C₈-alkenyloxy, substituted or non-substituted         C₃-C₈-alkynyloxy, substituted or non-substituted         N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or         non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-halogenoalkanimidoyl         having 1 to 5 halogen atoms, substituted or non-substituted         C₁-C₈-alkoxycarbonyl, substituted or non-substituted         C₁-C₈-alkylcarbonyloxy, substituted or non-substituted         C₁-C₈-alkylsulfinyl, substituted or non-substituted         C₁-C₈-alkylsulfonyl, substituted or non-substituted phenoxy,         substituted or non-substituted phenylsulfenyl, substituted or         non-substituted aryl, substituted or non-substituted         tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted         tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted         heterocyclyl, substituted or non-substituted heterocyclyloxy;

as well as salts, N-oxides, metallic complexes and metalloidic complexes thereof or (E) and (Z) isomers and mixtures thereof.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

Any of the compounds according to the invention can exist as one or more stereoisomers depending on the number of stereogenic units (as defined by the IUPAC rules) in the compound. The invention thus relates equally to all the stereoisomers, and to the mixtures of all the possible stereoisomers, in all proportions. The stereoisomers can be separated according to the methods which are known per se by the man ordinary skilled in the art.

Notably, the stereostructure of the oxime moiety present in the 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadiazol-5(4H)-one derivative of formula (I) includes (E) or (Z) isomer, and these stereoisomers form part of the present invention.

According to the invention, the following generic terms are generally used with the following meanings:

-   -   halogen means fluorine, chlorine, bromine or iodine;     -   heteroatom can be nitrogen, oxygen or sulfur;     -   unless indicated otherwise, a group or a substituent that is         substituted according to the invention can be substituted by one         or more of the following groups or atoms: a halogen atom, a         nitro group, a hydroxy group, a cyano group, an amino group, a         sulfenyl group, a pentafluoro-λ⁶-sulfenyl group, a formyl group,         a carbaldehyde O—(C₁-C₈-alkyl)oxime, a formyloxy group, a         formylamino group, a formylamino group, a         (hydroxyimino)-C₁-C₆-alkyl group, a C₁-C₈-alkyl, a         tri(C₁-C₈-alkyl)silyl, C₃-C₈-cycloalkyl, C₃-C₈-cycloalkenyl, a         C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, a         C₁-C₈-halogenocycloalkyl having 1 to 5 halogen atoms, a         C₂-C₈-alkenyl, a C₂-C₈-alkynyl, a C₂-C₈-alkenyloxy, a         C₂-C₈-alkynyloxy, a C₁-C₈-alkylamino, a di-C₁-C₈-alkylamino, a         C₁-C₈-alkoxy, a C₁-C₈-halogenoalkoxy having 1 to 5 halogen         atoms, a C₁-C₈-alkylsulfenyl, a C₁-C₈-halogenoalkylsulfenyl         having 1 to 5 halogen atoms, a C₂-C₈-halogenoalkenyloxy having 1         to 5 halogen atoms, a C₃-C₈-halogenoalkynyloxy having 1 to 5         halogen atoms, a C₁-C₈-alkylcarbonyl, a         C₁-C₈-halogenoalkylcarbonyl having 1 to 5 halogen atoms, a         C₁-C₈-alkylcarbamoyl, a di-C₁-C₈-alkylcarbamoyl, a         N—C₁-C₈-alkyloxycarbamoyl, a C₁-C₈-alkoxycarbamoyl, a         N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl, a C₁-C₈-alkoxycarbonyl, a         C₁-C₈-halogenoalkoxycarbonyl having 1 to 5 halogen atoms, a         C₁-C₈-alkylcarbonyloxy, a C₁-C₈-halogenoalkylcarbonyloxy having         1 to 5 halogen atoms, a C₁-C₈-alkylcarbonylamino, a         C₁-C₈-halogenoalkylcarbonylamino having 1 to 5 halogen atoms,         C₁-C₈-alkoxycarbonylamino, C₁-C₈-halogenoalkoxycarbonylamino         having 1 to 5 halogen atoms, a C₁-C₈-alkylaminocarbonyloxy, a         di-C₁-C₈-alkylaminocarbonyloxy, a C₁-C₈-alkyloxycarbonyloxy, a         (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, a         (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, a         (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl,         (benzyloxyimino)-C₁-C₆-alkyl, C₁-C₈-alkoxyalkyl,         C₁-C₈-halogenoalkoxyalkyl having 1 to 5 halogen atoms,         benzyloxy, benzylsulfenyl, benzylamino, phenoxy, phenylsulfenyl,         or phenylamino, an aryl group, an heterocyclyl group; or     -   a group or a substituent that is substituted according to the         invention can be substituted in a way that substituting groups         form together a substituted or non-substituted, saturated or         partially saturated 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, or         11-membered cycle, which can be a carbocycle or a heterocycle         comprising up to 4 heteroatoms selected from the list consisting         of N, O, and S     -   the term “aryl” means phenyl or naphthyl;     -   the term “heterocyclyl” means fused or non-fused, saturated or         unsaturated, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11- or 12-membered         ring comprising up to 4 heteroatoms selected in the list         consisting of N, O, S.     -   Where a compound of the invention can be present in tautomeric         form, such a compound is understood hereinabove and hereinbelow         also to include, where applicable, corresponding tautomeric         forms, even when these are not specifically mentioned in each         case.

Preferred compounds of formula (I) according to the invention are those wherein X¹ represents a hydrogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl or a substituted or non-substituted C₂-C₈-alkenyl.

More preferred compounds of formula (I) according to the invention are those wherein X¹ represents a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, an isopropyl group or a cyclopropyl group.

Even more preferred compounds of formula (I) according to the invention are those wherein X¹ represents a hydrogen atom or a methyl group.

Other preferred compounds of formula (I) according to the invention are those wherein Z¹ represents a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino;

More preferred compounds of formula (I) according to the invention are those wherein Z¹ represents substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino.

Even more preferred compounds of formula (I) according to the invention are those wherein Z¹ represents substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino.

Other preferred compounds of formula (I) according to the invention are those wherein Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl. More preferred compounds of formula (I) according to the invention are those wherein Z², Z³ and Z⁴ independently represent a hydrogen atom.

Other preferred compounds of formula (I) according to the invention are those wherein Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkoxy.

More preferred compounds of formula (I) according to the invention are those wherein Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, methyl, ethyl, isopropyl, isobutyl, tertbutyl, trifluoromethyl, difluoromethyl, allyl, ethynyl, propargyl, cyclopropyl, methoxy or trifluoromethoxy. Even more preferred compounds of formula (I) according to the invention are those wherein Y¹ to Y⁵ independently represent a hydrogen atom or fluorine atom.

The above mentioned preferences with regard to the substituents of the compounds of formula (I) according to the invention can be combined in various manners. These combinations of preferred features thus provide sub-classes of compounds according to the invention. Examples of such sub-classes of preferred compounds according to the invention can combine:

-   -   preferred features of A with preferred features of one or more         of X¹ to X³, Y¹ to Y⁵;     -   preferred features of X¹ with preferred features of one or more         of A, X², X³, Y¹ to Y⁵;     -   preferred features of X² with preferred features of one or more         of A, X¹, X³, Y¹ to Y⁵;     -   preferred features of X³ with preferred features of one or more         of A, X¹, X², Y¹ to Y⁵;     -   preferred features of Y¹ with preferred features of one or more         of A, X¹ to X³ and Y² to Y⁵;     -   preferred features of Y² with preferred features of one or more         of A, X¹ to X³, Y¹ and Y³ to Y⁵;     -   preferred features of Y³ with preferred features of one or more         of A, X¹ to X³, Y¹ Y² Y⁴ and Y⁵;     -   preferred features of Y⁴ with preferred features of one or more         of A, X¹ to X³, Y¹ to Y³ and Y⁵;     -   preferred features of Y⁵ with preferred features of one or more         of A, X¹ to X³ and Y¹ to Y⁴.

In these combinations of preferred features of the substituents of the compounds according to the invention, the said preferred features can also be selected among the more preferred features of each of A, X¹ to X³, and Y¹ to Y⁵; so as to form most preferred subclasses of compounds according to the invention.

The present invention also relates to a process for the preparation of compounds of formula (I).

Thus, according to a further aspect of the present invention, there is a provided a process P1 for the preparation of compounds of formula (Ia) from compounds of formula (II), by a reaction of nucleophilic substitution on compounds of formula (III) to yield to a compound of formula (IV), according to known methods, optionally in the presence of a base, according to known methods; followed by the addition of hydroxylamine or an hydroxylamine salt on compounds of formula (IV) to yield to a compound of formula (V), optionally in the presence of a base, optionally in the presence of an acid, according to known methods; followed by a reaction of cyclization of compounds of formula (V) to yield to a compound of formula (Ia), with a phosgene equivalent, optionally in the presence of a base, according to known methods; followed by a reaction of alkylation of compounds of formula (Ib) to yield to a compound of formula (Ia), with an alkylating agent of formula X¹-LGa, optionally in the presence of a base, according to known methods.

In such a case there is provided a process P1 according to the invention and such a process P1 can be illustrated by the following reaction scheme:

wherein Y¹, Y², Y³, Y⁴, Y⁵, A and X¹ are as herein-defined and LG and LGa independently represent a leaving group. Suitable leaving groups can be selected in the list consisting of a halogen atom or other customary nucleofugal groups such as triflate, mesylate, or tosylate.

Suitable acids for the transformation of compounds of formula (IV) into compounds of formula (V) can be chosen as being a mineral acid such as hydrogen chloride and sulfuric acid, and an organic acid such as formic acid and acetic acid.

Suitable phosgene equivalent for the conversion of compounds of formula (V) into a compound of formula (I) can be chosen as being phosgene, diphosgene, triphosgene, carbonyl di-imidazole, a chlorformate derivative, such as ethyl chloroformate and 4-nitrophenoxy-chloroformate.

Compounds of formula (II) and (III) are commercially available or are easily accessible to the skilled worker in the art. Examples of preparation can be found in world patent application WO2009/130193. Compounds of formula formula X¹-LGa are commercially available.

In such a case there is provided a further process P2 according to the invention and such a process P2 can be illustrated by the following reaction scheme:

wherein Y¹, Y², Y³, Y⁴, Y⁵, X¹ and A are as herein-defined.

Suitable phosgene equivalent for the conversion of compounds of formula (VI) into a compound of formula (I) can be chosen as being phosgene, diphosgene, triphosgene, carbonyl di-imidazole, a chlorformate derivative, such as ethyl chloroformate and 4-nitrophenoxy-chloroformate.

Hydroxylamine derivatives or an hydroxylamine derivative salts are commercially available or are easily accessible to the skilled worker in the art.

According to the invention, there is provided a further process P3 for the preparation of compounds of formula (Ie) from compounds of formula (Id), by a reaction of nucleophilic substitution to yield to a compound of formula (Ie), according to known methods, optionally in the presence of a catalyst notably a transition metal catalyst, such as palladium salts or complexes for example palladium (II) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(0), bis-(triphenylphosphine) palladium dichloride (II), tris(dibenzylideneacetone) dipalladium(0), bis(dibenzylideneacetone) palladium(0) or 1,1′-bis(diphenylphosphino)ferrocene-palladium (II) chloride. As an alternative the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri-tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert-butylphosphin)biphenyl, 2-(dicyclohexylphosphine)-2′-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3-(diphenylphosphino)benzolsulfonate, tris-2-(methoxyphenyl)phosphine, 2,2′-bis-(diphenylphosphine)-1,1′-binaphthyl, 1,4-bis-(diphenylphosphine)butane, 1,2-bis-(diphenylphosphine)ethane, 1,4-bis-(dicyclohexylphosphine)butane, 1,2-bis-(dicyclohexylphosphine)ethane, 2-(dicyclohexylphosphine)-2′-(N,N-dimethylamino)-biphenyl, bis(diphenylphosphino)ferrocene, tris-(2,4-tert-butylphenyl)-phosphite, (R)-(−)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine, (S)-(+)-1-[(R)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (R)-(−)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine, (S)-(+)-1-[(R)-2-(diphenylphosphino)ferrocenyl]ethyldi-t-butylphosphine, optionally in the presence of a base such as an inorganic or an organic base; preferably an alkaline earth metal or alkali metal hydride, hydroxide, amide, alcoholate, acetate, carbonate or hydrogen carbonate, such as sodium hydride, sodium amide, lithium diisopropylamide, sodium methanolate, sodium ethanolate, potassium tert-butanolate, sodium acetate, potassium acetate, calcium acetate, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate or ammonium carbonate; and also tertiary amine, such as trimethylamine, triethylamine (TEA), tributylamine, N,N-dimethylaniline, N,N-dimethyl-benzylamine, N,N-diisopropyl-ethylamine (DIPEA), pyridine, N-methylpiperidine, N-methylmorpholine, N,N-dimethylaminopyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicycloundecene (DBU), according to known methods. In such a case there is provided a process P3 according to the invention and such a process P4 can be illustrated by the following reaction scheme:

wherein

-   -   Y¹, Y², Y³, Y⁴, Y⁵, X¹, X² and X³ are as herein-defined and         A_(d) represents A wherein Z¹ represents a halogen atom; A_(c)         represents A wherein Z¹ represents a hydroxy group, a cyano         group, a sulfenyl group, a formyloxy group, substituted or         non-substituted (C₁-C₃-alkylamino)-amino group, substituted or         non-substituted N—C₁-C₈-alkyl-(C₁-C₈-alkylamino)-amino group,         substituted or non-substituted C₁-C₈-alkyl, substituted or         non-substituted C₃-C₈-cycloalkyl, a C₂-C₈-alkenyl, substituted         or non-substituted C₂-C₈-alkynyl, substituted or non-substituted         C₁-C₈-alkoxy, substituted or non-substituted C₂-C₈-alkenyloxy,         substituted or non-substituted C₃-C₈-alkynyloxy, substituted or         non-substituted C₁-C₈-alkylcarbonyloxy, substituted or         non-substituted N—C₁-C₈-alkylaminocarbonyloxy, substituted or         non-substituted N,N′-di-C₁-C₈-alkylaminocarbonyloxy, substituted         or non-substituted (C₁-C₈-alkyl-carbamothioyl)-oxy, substituted         or non-substituted substituted or non-substituted         (di-C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or         non-substituted C₁-C₈-alkylsulfenyl, substituted or         non-substituted C₁-C₈-halogenoalkylsulfenyl having 1 to 5         halogen atoms, substituted or non-substituted         C₁-C₈-alkylsulfinyl, substituted or non-substituted phenoxy,         substituted or non-substituted phenylsulfenyl, substituted or         non-substituted aryl, substituted or non-substituted         (C₁-C₈-alkylideneamino)oxy, substituted or non-substituted         (C₁-C₈-alkenylideneamino)oxy, substituted or non-substituted         (C₁-C₈-alkynylideneamino)oxy, substituted or non-substituted         (benzylideneamino)oxy;

The present invention also relates to a process for the preparation of compounds of formula (Ia). Thus, according to a further aspect of the present invention, there is a provided a process P4 for the preparation of compounds of formula (Ia) from compounds of formula (VII), by a reaction of oxidation compounds of formula (VII) in a presence of a suitable oxidizing agent to yield to a compound of compounds of formula (VIII), followed by a condensation of compounds of formula (IX), optionally under microwave irradiation, optionally in the presence of a dehydrating agent, such as molecular sieves, to yield to compounds of formula (Ia), according to known methods. In such a case there is provided a process P4, according to the invention and such a process P4 can be illustrated by the following reaction scheme:

wherein Y¹, Y², Y³, Y⁴ Y⁵, A and X¹ are as herein-defined.

Examples of oxidations at the methylene position between a phenyl ring and an heterocycle to yield an oxo substituent are known and can be found for example in Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1982), (12), 2995-3006. Suitable oxidizing agents for carrying out the first step of process P5 according to the invention can be inorganic and organic peroxides such as hydrogen peroxide and benzoyl peroxide, metallic and metalloidic oxides such as manganese (IV) oxide, chromium (VI) oxide, oxygen optionally in the presence of singlet oxygen activator, halogenating agents in an aqueous medium such as bleach.

Compounds of formula (VII) are easily accessible to the skilled worker in the art. Examples of preparation can be found in Annali di Chimica (Rome, Italy), (1963), 53(10), 1405-10

Examples of condensations of compounds of formula (VIII) with compounds of formula (IX) can be found in world patent application WO2010/000841.

Compounds of formula (IX) are easily accessible to the skilled worker in the art. Examples of preparation can be found in world patent application WO2010/000841.

According to the invention, there is provided a further process P5 for the preparation of compounds of formula (Ig) from compounds of formula (If) by reaction with a compound of formula (X) followed by reaction with a compound of formula (XI) according to the following reaction scheme.

Wherein

-   -   T, X¹, X², X³ are as herein-defined;     -   A_(f) represents A wherein Z¹ represents —NH₂;     -   A_(g) represents A wherein Z¹ represents substituted or         non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino or         substituted or non-substituted         (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino     -   R¹, R², R⁵ and R⁶ represents alkyl     -   R³ and R⁷ represents hydrogen or alkyl

Compounds of formula (X) and (XI) are commercially available or are easily accessible to the skilled worker in the art.

According to the invention, there is provided a further process P6 for the preparation of compounds of formula (Ii) from compounds of formula (Ih) by alkylation with a compound of formula (XII) according to the following reaction scheme.

Wherein

-   -   T, X¹, X², X³ are as herein-defined;     -   A_(f) represents A wherein Z¹ represents substituted or         non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino     -   A_(g) represents A wherein Z¹ represents substituted or         non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino     -   R⁸ represents an alkyl group     -   LG represents a leaving group

Compounds of formula (XII) are commercially available or are easily accessible to the skilled worker in the art.

According to the invention, processes P1 to P6 can be performed if appropriate in the presence of a solvent and if appropriate in the presence of a base.

Suitable solvents for carrying out processes P1 to P6 according to the invention are customary inert organic solvents. Preference is given to using optionally halogenated aliphatic, alicyclic or aromatic hydrocarbons, such as petroleum ether, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin; chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichlorethane or trichlorethane; ethers, such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, methyl tert-amyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane, 1,2-diethoxyethane or anisole; nitriles, such as acetonitrile, propionitrile, n- or iso-butyronitrile or benzonitrile; amides, such as N,N-dimethylformamide, N,N-dimethylacetamide, N-methylformanilide, N-methylpyrrolidone or hexamethylphosphoric triamide; esters, such as methyl acetate or ethyl acetate, sulfoxides, such as dimethyl sulfoxide or sulfones, such as sulfolane.

Suitable bases for carrying out processes P1 to P6 according to the invention are inorganic and organic bases which are customary for such reactions. Preference is given to using alkaline earth metal, alkali metal hydride, alkali metal hydroxides or alkali metal alkoxides, such as sodium hydroxide, sodium hydride, calcium hydroxide, potassium hydroxide, potassium tert-butoxide or other ammonium hydroxide, alkali metal carbonates, such as sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate, alkali metal or alkaline earth metal acetates, such as sodium acetate, potassium acetate, calcium acetate and also tertiary amines, such as trimethylamine, triethylamine, diisopropylethylamine, tributylamine, N,N-dimethylaniline, pyridine, N-methylpiperidine, N,N-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane (DABCO), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU).

If carrying out processes P1 to P6, according to the invention, the reaction temperature can independently be varied within a relatively wide range. Generally, process P1 according to the invention is carried out at temperatures between −20° C. and 160° C.

Processes P1 to P6 according to the invention are generally independently carried out under atmospheric pressure. However, it is also possible to operate under elevated or reduced pressure.

Work-up is carried out by customary methods. Generally, the reaction mixture is treated with water and the organic phase is separated off and, after drying, concentrated under reduced pressure. If appropriate, the remaining residue can be freed by customary methods, such as chromatography or recrystallization, from any impurities that can still be present.

Compounds according to the invention can be prepared according to the above described processes. It will nevertheless be understood that, on the basis of his general knowledge and of available publications, the skilled worker will be able to adapt these processes according to the specifics of each of the compounds according to the invention that is desired to be synthesised.

The compounds of formula (IV) can be advantageously prepared according to the method described in WO2011/080254, hereby incorporated by reference.

In a further aspect, the present invention relates to compounds of formula (V) useful as intermediate compounds or materials for the process of preparation according to the invention.

The present invention thus provides compounds of formula (V) wherein Y¹, Y², Y³, Y⁴, Y⁵ and A are as herein-defined.

In a further aspect, the present invention relates to compounds of formula (VI) useful as intermediate compounds or materials for the process of preparation according to the invention.

The present invention thus provides compounds of formula (VI) wherein Y¹, Y², Y³, Y⁴, Y⁵, X¹ and A are as herein-defined.

In a further aspect, the present invention also relates to a fungicide composition comprising an effective and non-phytotoxic amount of an active compound of formula (I).

The expression “effective and non-phytotoxic amount” means an amount of composition according to the invention which is sufficient to control or destroy the fungi present or liable to appear on the crops and which does not entail any appreciable symptom of phytotoxicity for the said crops. Such an amount can vary within a wide range depending on the fungus to be controlled, the type of crop, the climatic conditions and the compounds included in the fungicide composition according to the invention. This amount can be determined by systematic field trials, which are within the capabilities of a person skilled in the art.

Thus, according to the invention, there is provided a fungicide composition comprising, as an active ingredient, an effective amount of a compound of formula (I) as herein defined and an agriculturally acceptable support, carrier or filler.

According to the invention, the term “support” denotes a natural or synthetic organic or inorganic compound with which the active compound of formula (I) is combined or associated to make it easier to apply, notably to the parts of the plant. This support is thus generally inert and should be agriculturally acceptable. The support can be a solid or a liquid. Examples of suitable supports include clays, natural or synthetic silicates, silica, resins, waxes, solid fertilisers, water, alcohols, in particular butanol organic solvents, mineral and plant oils and derivatives thereof. Mixtures of such supports can also be used.

The composition according to the invention can also comprise additional components. In particular, the composition can further comprise a surfactant. The surfactant can be an emulsifier, a dispersing agent or a wetting agent of ionic or non-ionic type or a mixture of such surfactants. Mention can be made, for example, of polyacrylic acid salts, lignosulfonic acid salts, phenolsulfonic or naphthalenesulfonic acid salts, polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines, substituted phenols (in particular alkylphenols or arylphenols), salts of sulfosuccinic acid esters, taurine derivatives (in particular alkyl taurates), phosphoric esters of polyoxyethylated alcohols or phenols, fatty acid esters of polyols and derivatives of the above compounds containing sulfate, sulfonate and phosphate functions. The presence of at least one surfactant is generally essential if the active compound and/or the inert support are water-insoluble and if the vector agent for the application is water. Preferably, surfactant content can be comprised from 5% to 40% by weight of the composition.

Optionally, additional components can also be included, e.g. protective colloids, adhesives, thickeners, thixotropic agents, penetration agents, stabilisers, sequestering agents. More generally, the active compounds can be combined with any solid or liquid additive, which complies with the usual formulation techniques.

In general, the composition according to the invention can contain from 0.05 to 99% by weight of active compound, preferably 10 to 70% by weight.

Compositions according to the invention can be used in various forms such as aerosol dispenser, capsule suspension, cold fogging concentrate, dustable powder, emulsifiable concentrate, emulsion oil in water, emulsion water in oil, encapsulated granule, fine granule, flowable concentrate for seed treatment, gas (under pressure),gas generating product, granule, hot fogging concentrate, macrogranule, microgranule, oil dispersible powder, oil miscible flowable concentrate, oil miscible liquid, paste, plant rodlet, powder for dry seed treatment, seed coated with a pesticide, soluble concentrate, soluble powder, solution for seed treatment, suspension concentrate (flowable concentrate), ultra low volume (ULV) liquid, ultra low volume (ULV) suspension, water dispersible granules or tablets, water dispersible powder for slurry treatment, water soluble granules or tablets, water soluble powder for seed treatment and wettable powder. These compositions include not only compositions which are ready to be applied to the plant or seed to be treated by means of a suitable device, such as a spraying or dusting device, but also concentrated commercial compositions which must be diluted before application to the crop.

The compounds according to the invention can also be mixed with one or more insecticide, fungicide, bactericide, attractant, acaricide or pheromone active substance or other compounds with biological activity. The mixtures thus obtained have a broadened spectrum of activity. The mixtures with other fungicide compounds are particularly advantageous. The composition according to the invention comprising a mixture of a compound of formula (I) with a bactericide compound can also be particularly advantageous.

According to another object of the present invention, there is provided a method for controlling the phytopathogenic fungi of plants, crops or seeds, characterized in that an agronomically effective and substantially non-phytotoxic quantity of a pesticide composition according to the invention is applied as seed treatment, foliar application, stem application, drench or drip application (chemigation) to the seed, the plant or to the fruit of the plant or to soil or to inert substrate (e.g. inorganic substrates like sand, rockwool, glasswool; expanded minerals like perlite, vermiculite, zeolite or expanded clay), Pumice, Pyroclastic materials or stuff, synthetic organic substrates (e.g. polyurethane) organic substrates (e.g. peat, composts, tree waste products like coir, wood fibre or chips, tree bark) or to a liquid substrate (e.g. floating hydroponic systems, Nutrient Film Technique, Aeroponics) wherein the plant is growing or wherein it is desired to grow.

The expression “are applied to the plants to be treated” is understood to mean, for the purposes of the present invention, that the pesticide composition which is the subject of the invention can be applied by means of various methods of treatment such as:

-   -   spraying onto the aerial parts of the said plants a liquid         comprising one of the said compositions,     -   dusting, the incorporation into the soil of granules or powders,         spraying, around the said plants and in the case of trees         injection or daubing,     -   coating or film-coating the seeds of the said plants with the         aid of a plant-protection mixture comprising one of the said         compositions.

The method according to the invention can either be a curing, preventing or eradicating method.

In this method, a composition used can be prepared beforehand by mixing the two or more active compounds according to the invention.

According to an alternative of such a method, it is also possible to apply simultaneously, successively or separately compounds (A) and (B) so as to have the conjugated (A)/(B) effects, of distinct compositions each containing one of the two or three active ingredients (A) or (B).

The dose of active compound usually applied in the method of treatment according to the invention is generally and advantageously

-   -   for foliar treatments: from 0.1 to 10,000 g/ha, preferably from         10 to 1,000 g/ha, more preferably from 50 to 300 g/ha; in case         of drench or drip application, the dose can even be reduced,         especially while using inert substrates like rockwool or         perlite;     -   for seed treatment: from 2 to 200 g per 100 kilogram of seed,         preferably from 3 to 150 g per 100 kilogram of seed;     -   for soil treatment: from 0.1 to 10,000 g/ha, preferably from 1         to 5,000 g/ha.

The doses herein indicated are given as illustrative Examples of method according to the invention. A person skilled in the art will know how to adapt the application doses, notably according to the nature of the plant or crop to be treated.

Under specific conditions, for example according to the nature of the phytopathogenic fungus to be treated or controlled, a lower dose can offer adequate protection. Certain climatic conditions, resistance or other factors like the nature of the phytopathogenic fungi or the degree of infestation, for example, of the plants with these fungi, can require higher doses of combined active ingredients. The optimum dose usually depends on several factors, for example on the type of phytopathogenic fungus to be treated, on the type or level of development of the infested plant, on the density of vegetation or alternatively on the method of application.

Without it being limiting, the crop treated with the pesticide composition or combination according to the invention is, for example, grapevine, but this could be cereals, vegetables, lucerne, soybean, market garden crops, turf, wood, tree or horticultural plants.

The method of treatment according to the invention can also be useful to treat propagation material such as tubers or rhizomes, but also seeds, seedlings or seedlings pricking out and plants or plants pricking out. This method of treatment can also be useful to treat roots. The method of treatment according to the invention can also be useful to treat the over-ground parts of the plant such as trunks, stems or stalks, leaves, flowers and fruit of the concerned plant.

Among the plants that can be protected by the method according to the invention, mention can be made of cotton; flax; vine; fruit or vegetable crops such as Rosaceae sp. (for instance pip fruit such as apples and pears, but also stone fruit such as apricots, almonds and peaches), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (for instance banana trees and plantins), Rubiaceae sp., Theaceae sp., Sterculiceae sp., Rutaceae sp. (for instance lemons oranges and grapefruit); Solanaceae sp. (for instance tomatoes), Liliaceae sp., Asteraceae sp. (for instance lettuces), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbitaceae sp., Papilionaceae sp. (for instance peas), Rosaceae sp. (for instance strawberries); major crops such as Graminae sp. (for instance maize, lawn or cereals such as wheat, rice, barley and triticale), Asteraceae sp. (for instance sunflower), Cruciferae sp. (for instance colza), Fabacae sp. (for instance peanuts), Papilionaceae sp. (for instance soybean), Solanaceae sp. (for instance potatoes), Chenopodiaceae sp. (for instance beetroots); horticultural and forest crops; as well as genetically modified homologues of these crops.

The method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds. Genetically modified plants (or transgenic plants) are plants in which a heterologous gene has been stably integrated into the genome. The expression “heterologous gene” essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, co suppression technology or RNA interference—RNAi—technology). A heterologous gene that is located in the genome is also called a transgene. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive (“synergistic”) effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the active compounds and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, bigger fruits, larger plant height, greener leaf color, earlier flowering, higher quality and/or a higher nutritional value of the harvested products, higher sugar concentration within the fruits, better storage stability and/or processability of the harvested products are possible, which exceed the effects which were actually to be expected.

At certain application rates, the active compound combinations according to the invention may also have a strengthening effect in plants. Accordingly, they are also suitable for mobilizing the defense system of the plant against attack by unwanted phytopathogenic fungi and/or microorganisms and/or viruses. This may, if appropriate, be one of the reasons of the enhanced activity of the combinations according to the invention, for example against fungi. Plant-strengthening (resistance-inducing) substances are to be understood as meaning, in the present context, those substances or combinations of substances which are capable of stimulating the defense system of plants in such a way that, when subsequently inoculated with unwanted phytopathogenic fungi and/or microorganisms and/or viruses, the treated plants display a substantial degree of resistance to these unwanted phytopathogenic fungi and/or microorganisms and/or viruses. In the present case, unwanted phytopathogenic fungi and/or microorganisms and/or viruses are to be understood as meaning phytopathogenic fungi, bacteria and viruses. Thus, the substances according to the invention can be employed for protecting plants against attack by the abovementioned pathogens within a certain period of time after the treatment. The period of time within which protection is effected generally extends from 1 to 10 days, preferably 1 to 7 days, after the treatment of the plants with the active compounds.

Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).

Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.

Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses. Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozon exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.

Plants and plant cultivars which may also be treated according to the invention, are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation. Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance. Further yield traits include seed composition, such as carbohydrate content, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.

Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stress factors. Such plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another inbred male-fertile parent line (the male parent). Hybrid seed is typically harvested from the male sterile plants and sold to growers. Male sterile plants can sometimes (e.g. in corn) be produced by detasseling, i.e. the mechanical removal of the male reproductive organs (or males flowers) but, more typically, male sterility is the result of genetic determinants in the plant genome. In that case, and especially when seed is the desired product to be harvested from the hybrid plants it is typically useful to ensure that male fertility in the hybrid plants is fully restored. This can be accomplished by ensuring that the male parents have appropriate fertility restorer genes which are capable of restoring the male fertility in hybrid plants that contain the genetic determinants responsible for male-sterility. Genetic determinants for male sterility may be located in the cytoplasm. Examples of cytoplasmic male sterility (CMS) were for instance described in Brassica species (WO 1992/005251, WO 1995/009910, WO 1998/27806, WO 2005/002324, WO 2006/021972 and U.S. Pat. No. 6,229,072). However, genetic determinants for male sterility can also be located in the nuclear genome. Male sterile plants can also be obtained by plant biotechnology methods such as genetic engineering. A particularly useful means of obtaining male-sterile plants is described in WO 1989/10396 in which, for example, a ribonuclease such as barnase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expression in the tapetum cells of a ribonuclease inhibitor such as barstar (e.g. WO 1991/002069).

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may be treated according to the invention are herbicide-tolerant plants, i.e. plants made tolerant to one or more given herbicides. Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.

Herbicide-tolerant plants are for example glyphosate-tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or salts thereof. Plants can be made tolerant to glyphosate through different means. For example, glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS). Examples of such EPSPS genes are the AroA gene (mutant CT7) of the bacterium Salmonella typhimurium, the CP4 gene of the bacterium Agrobacterium sp., the genes encoding a Petunia EPSPS, a Tomato EPSPS, or an Eleusine EPSPS (WO 2001/66704). It can also be a mutated EPSPS as described in for example EP-A 0837944, WO 2000/066746, WO 2000/066747 or WO 2002/026995. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate oxido-reductase enzyme as described in U.S. Pat. Nos. 5,776,760 and 5,463,175. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate acetyl transferase enzyme as described in for example WO 2002/036782, WO 2003/092360, WO 2005/012515 and WO 2007/024782. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally-occurring mutations of the above-mentioned genes, as described in for example WO 2001/024615 or WO 2003/013226.

Other herbicide resistant plants are for example plants that are made tolerant to herbicides inhibiting the enzyme glutamine synthase, such as bialaphos, phosphinothricin or glufosinate. Such plants can be obtained by expressing an enzyme detoxifying the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition. One such efficient detoxifying enzyme is an enzyme encoding a phosphinothricin acetyltransferase (such as the bar or pat protein from Streptomyces species). Plants expressing an exogenous phosphinothricin acetyltransferase are for example described in U.S. Pat. Nos. 5,561,236; 5,648,477; 5,646,024; 5,273,894; 5,637,489; 5,276,268; 5,739,082; 5,908,810 and 7,112,665.

Further herbicide-tolerant plants are also plants that are made tolerant to the herbicides inhibiting the enzyme hydroxyphenylpyruvatedioxygenase (HPPD). Hydroxyphenylpyruvatedioxygenases are enzymes that catalyze the reaction in which para-hydroxyphenylpyruvate (HPP) is transformed into homogentisate. Plants tolerant to HPPD-inhibitors can be transformed with a gene encoding a naturally-occurring resistant HPPD enzyme, or a gene encoding a mutated HPPD enzyme as described in WO 1996/038567, WO 1999/024585 and WO 1999/024586. Tolerance to HPPD-inhibitors can also be obtained by transforming plants with genes encoding certain enzymes enabling the formation of homogentisate despite the inhibition of the native HPPD enzyme by the HPPD-inhibitor. Such plants and genes are described in WO 1999/034008 and WO 2002/36787. Tolerance of plants to HPPD inhibitors can also be improved by transforming plants with a gene encoding an enzyme prephenate dehydrogenase in addition to a gene encoding an HPPD-tolerant enzyme, as described in WO 2004/024928.

Still further herbicide resistant plants are plants that are made tolerant to acetolactate synthase (ALS) inhibitors. Known ALS-inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pyrimidinyloxy(thio)benzoates, and/or sulfonylaminocarbonyltriazolinone herbicides. Different mutations in the ALS enzyme (also known as acetohydroxyacid synthase, AHAS) are known to confer tolerance to different herbicides and groups of herbicides, as described for example in U.S. Pat. Nos. 5,605,011, 5,378,824, 5,141,870, and 5,013,659. The production of sulfonylurea-tolerant plants and imidazolinone-tolerant plants is described in U.S. Pat. Nos. 5,605,011; 5,013,659; 5,141,870; 5,767,361; 5,731,180; 5,304,732; 4,761,373; 5,331,107; 5,928,937; and 5,378,824; and international publication WO 1996/033270. Other imidazolinone-tolerant plants are also described in for example WO 2004/040012, WO 2004/106529, WO 2005/020673, WO 2005/093093, WO 2006/007373, WO 2006/015376, WO 2006/024351, and WO 2006/060634. Further sulfonylurea- and imidazolinone-tolerant plants are also described in for example WO 2007/024782.

Other plants tolerant to imidazolinone and/or sulfonylurea can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or mutation breeding as described for example for soybeans in U.S. Pat. No. 5,084,082, for rice in WO 1997/41218, for sugar beet in U.S. Pat. No. 5,773,702 and WO 1999/057965, for lettuce in U.S. Pat. No. 5,198,599, or for sunflower in WO 2001/065922.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.

An “insect-resistant transgenic plant”, as used herein, includes any plant containing at least one transgene comprising a coding sequence encoding:

-   -   1) an insecticidal crystal protein from Bacillus thuringiensis         or an insecticidal portion thereof, such as the insecticidal         crystal proteins or insecticidal portions thereof, e.g.,         proteins of the Cry protein classes Cry1Ab, Cry1Ac, Cry1F,         Cry2Ab, Cry3Aa, or Cry3Bb or insecticidal portions thereof; or     -   2) a crystal protein from Bacillus thuringiensis or a portion         thereof which is insecticidal in the presence of a second other         crystal protein from Bacillus thuringiensis or a portion         thereof, such as the binary toxin made up of the Cry34 and Cry35         crystal proteins; or     -   3) a hybrid insecticidal protein comprising parts of different         insecticidal crystal proteins from Bacillus thuringiensis, such         as a hybrid of the proteins of 1) above or a hybrid of the         proteins of 2) above, e.g., the Cry1A.105 protein produced by         corn event MON98034 (WO 2007/027777); or     -   4) a protein of any one of 1) to 3) above wherein some,         particularly 1 to 10, amino acids have been replaced by another         amino acid to obtain a higher insecticidal activity to a target         insect species, and/or to expand the range of target insect         species affected, and/or because of changes introduced into the         encoding DNA during cloning or transformation, such as the         Cry3Bb1 protein in corn events MON863 or MON88017, or the Cry3A         protein in corn event MIR604;     -   5) an insecticidal secreted protein from Bacillus thuringiensis         or Bacillus cereus, or an insecticidal portion thereof, such as         the vegetative insecticidal (VIP) proteins; or     -   6) a secreted protein from Bacillus thuringiensis or Bacillus         cereus which is insecticidal in the presence of a second         secreted protein from Bacillus thuringiensis or B. cereus, such         as the binary toxin made up of the VIP1A and VIP2A proteins (WO         1994/21795); or     -   7) a hybrid insecticidal protein comprising parts from different         secreted proteins from Bacillus thuringiensis or Bacillus         cereus, such as a hybrid of the proteins in 1) above or a hybrid         of the proteins in 2) above; or     -   8) a protein of any one of 1) to 3) above wherein some,         particularly 1 to 10, amino acids have been replaced by another         amino acid to obtain a higher insecticidal activity to a target         insect species, and/or to expand the range of target insect         species affected, and/or because of changes introduced into the         encoding DNA during cloning or transformation (while still         encoding an insecticidal protein), such as the VIP3Aa protein in         cotton event COT102.

Of course, an insect-resistant transgenic plant, as used herein, also includes any plant comprising a combination of genes encoding the proteins of any one of the above classes 1 to 8. In one embodiment, an insect-resistant plant contains more than one transgene encoding a protein of any one of the above classes 1 to 8, to expand the range of target insect species affected when using different proteins directed at different target insect species, or to delay insect resistance development to the plants by using different proteins insecticidal to the same target insect species but having a different mode of action, such as binding to different receptor binding sites in the insect.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance. Particularly useful stress tolerance plants include:

-   -   a. plants which contain a transgene capable of reducing the         expression and/or the activity of poly(ADP-ribose)polymerase         (PARP) gene in the plant cells or plants as described in WO         2000/004173 or W02006/045633 or PCT/EP07/004142.     -   b. plants which contain a stress tolerance enhancing transgene         capable of reducing the expression and/or the activity of the         PARG encoding genes of the plants or plants cells, as described         e.g. in WO 2004/090140.     -   c. plants which contain a stress tolerance enhancing transgene         coding for a plant-functional enzyme of the nicotinamide adenine         dinucleotide salvage synthesis pathway including nicotinamidase,         nicotinate phosphoribosyltransferase, nicotinic acid         mononucleotide adenyl transferase, nicotinamide adenine         dinucleotide synthetase or nicotine amide         phosphoribosyltransferase as described e.g. in WO2006/032469 or         WO 2006/133827 or PCT/EP07/002433.

Plants or plant cultivars (obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention show altered quantity, quality and/or storage-stability of the harvested product and/or altered properties of specific ingredients of the harvested product such as:

-   -   1) transgenic plants which synthesize a modified starch, which         in its physical-chemical characteristics, in particular the         amylose content or the amylose/amylopectin ratio, the degree of         branching, the average chain length, the side chain         distribution, the viscosity behaviour, the gelling strength, the         starch grain size and/or the starch grain morphology, is changed         in comparison with the synthesised starch in wild type plant         cells or plants, so that this is better suited for special         applications. Said transgenic plants synthesizing a modified         starch are disclosed, for example, in EP 0571427, WO         1995/004826, EP 0719338, WO 1996/15248, WO 1996/19581, WO         1996/27674, WO 1997/11188, WO 1997/26362, WO 1997/32985, WO         1997/42328, WO 1997/44472, WO 1997/45545, WO 1998/27212, WO         1998/40503, WO99/58688, WO 1999/58690, WO 1999/58654, WO         2000/008184, WO 2000/008185, WO 2000/008175, WO 2000/28052, WO         2000/77229, WO 2001/12782, WO 2001/12826, WO 2002/101059, WO         2003/071860, WO 2004/056999, WO 2005/030942, WO 2005/030941, WO         2005/095632, WO 2005/095617, WO 2005/095619, WO 2005/095618, WO         2005/123927, WO 2006/018319, WO 2006/103107, WO 2006/108702, WO         2007/009823, WO 2000/22140, WO 2006/063862, WO 2006/072603, WO         2002/034923, EP 06090134.5, EP 06090228.5, EP 06090227.7, EP         07090007.1, EP 07090009.7, WO 2001/14569, WO 2002/79410, WO         2003/33540, WO 2004/078983, WO 2001/19975, WO 1995/26407, WO         1996/34968, WO 1998/20145, WO 1999/12950, WO 1999/66050, WO         1999/53072, U.S. Pat. No. 6,734,341, WO 2000/11192, WO         1998/22604, WO 1998/32326, WO 2001/98509, WO 2001/98509, WO         2005/002359, U.S. Pat. Nos. 5,824,790, 6,013,861, WO         1994/004693, WO 1994/009144, WO 1994/11520, WO 1995/35026, WO         1997/20936.     -   2) transgenic plants which synthesize non starch carbohydrate         polymers or which synthesize non starch carbohydrate polymers         with altered properties in comparison to wild type plants         without genetic modification. Examples are plants producing         polyfructose, especially of the inulin and levan-type, as         disclosed in EP 0663956, WO 1996/001904, WO 1996/021023, WO         1998/039460, and WO 1999/024593, plants producing alpha 1,4         glucans as disclosed in WO 1995/031553, US 2002/031826, U.S.         Pat. Nos. 6,284,479, 5,712,107, WO 1997/047806, WO 1997/047807,         WO 1997/047808 and WO 2000/014249, plants producing alpha-1,6         branched alpha-1,4-glucans, as disclosed in WO 2000/73422,         plants producing alternan, as disclosed in WO 2000/047727, EP         06077301.7, U.S. Pat. No. 5,908,975 and EP 0728213,     -   3) transgenic plants which produce hyaluronan, as for example         disclosed in WO 2006/032538, WO 2007/039314, WO 2007/039315, WO         2007/039316, JP 2006/304779, and WO 2005/012529.

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics. Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics and include:

-   -   a) Plants, such as cotton plants, containing an altered form of         cellulose synthase genes as described in WO 1998/000549     -   b) Plants, such as cotton plants, containing an altered form of         rsw2 or rsw3 homologous nucleic acids as described in         WO2004/053219     -   c) Plants, such as cotton plants, with increased expression of         sucrose phosphate synthase as described in WO 2001/017333     -   d) Plants, such as cotton plants, with increased expression of         sucrose synthase as described in WO02/45485     -   e) Plants, such as cotton plants, wherein the timing of the         plasmodesmatal gating at the basis of the fiber cell is altered,         e.g. through downregulation of fiberselective β 1,3-glucanase as         described in WO2005/017157     -   f) Plants, such as cotton plants, having fibers with altered         reactivity, e.g. through the expression of         N-acteylglucosaminetransferase gene including nodC and         chitinsynthase genes as described in WO2006/136351

Plants or plant cultivars (that can be obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics. Such plants can be obtained by genetic transformation or by selection of plants contain a mutation imparting such altered oil characteristics and include:

-   -   a) Plants, such as oilseed rape plants, producing oil having a         high oleic acid content as described e.g. in U.S. Pat. Nos.         5,969,169, 5,840,946 or 6,323,392 or 6,063,947     -   b) Plants such as oilseed rape plants, producing oil having a         low linolenic acid content as described in U.S. Pat. Nos.         6,270828, 6,169,190 or 5,965,755     -   c) Plant such as oilseed rape plants, producing oil having a low         level of saturated fatty acids as described e.g. in U.S. Pat.         No. 5,434,283

Particularly useful transgenic plants which may be treated according to the invention are plants which comprise one or more genes which encode one or more toxins, such as the following which are sold under the trade names YIELD GARD® (for example maize, cotton, soya beans), KnockOut® (for example maize), BiteGard® (for example maize), Bt-Xtra® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucotn® (cotton), Nucotn 33B® (cotton), NatureGard® (for example maize), Protecta® and NewLeaf® (potato). Examples of herbicide-tolerant plants which may be mentioned are maize varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example maize, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulfonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned include the varieties sold under the name Clearfield® (for example maize).

The composition according to the invention can also be used against fungal diseases liable to grow on or inside timber. The term “timber” means all types of species of wood and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood and plywood. The method for treating timber according to the invention mainly consists in contacting one or more compounds according to the invention or a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.

Among the diseases of plants or crops that can be controlled by the method according to the invention, mention can be made of:

-   Powdery mildew diseases such as:     -   Blumeria diseases, caused for example by Blumeria graminis;     -   Podosphaera diseases, caused for example by Podosphaera         leucotricha;     -   Sphaerotheca diseases, caused for example by Sphaerotheca         fuliginea;     -   Uncinula diseases, caused for example by Uncinula necator; -   Rust diseases such as:     -   Gymnosporangium diseases, caused for example by Gymnosporangium         sabinae;     -   Hemileia diseases, caused for example by Hemileia vastatrix;     -   Phakopsora diseases, caused for example by Phakopsora pachyrhizi         or Phakopsora meibomiae;     -   Puccinia diseases, caused for example by Puccinia recondita;     -   Uromyces diseases, caused for example by Uromyces         appendiculatus; -   Oomycete diseases such as:     -   Bremia diseases, caused for example by Bremia lactucae;     -   Peronospora diseases, caused for example by Peronospora pisi         or P. brassicae;     -   Phytophthora diseases, caused for example by Phytophthora         infestans;     -   Plasmopara diseases, caused for example by Plasmopara viticola;     -   Pseudoperonospora diseases, caused for example by         Pseudoperonospora humuli or Pseudoperonospora cubensis;     -   Pythium diseases, caused for example by Pythium ultimum; -   Leafspot, leaf blotch and leaf blight diseases such as:     -   Alternaria diseases, caused for example by Alternaria solani;     -   Cercospora diseases, caused for example by Cercospora beticola;     -   Cladiosporum diseases, caused for example by Cladiosporium         cucumerinum;     -   Cochliobolus diseases, caused for example by Cochliobolus         sativus;     -   Colletotrichum diseases, caused for example by Colletotrichum         lindemuthanium;     -   Cycloconium diseases, caused for example by Cycloconium         oleaginum;     -   Diaporthe diseases, caused for example by Diaporthe citri;     -   Elsinoe diseases, caused for example by Elsinoe fawcettii;     -   Gloeosporium diseases, caused for example by Gloeosporium         laeticolor;     -   Glomerella diseases, caused for example by Glomerella cingulata;     -   Guignardia diseases, caused for example by Guignardia bidwelli;     -   Leptosphaeria diseases, caused for example by Leptosphaeria         maculans; Leptosphaeria nodorum;     -   Magnaporthe diseases, caused for example by Magnaporthe grisea;     -   Mycosphaerella diseases, caused for example by Mycosphaerella         graminicola; Mycosphaerella arachidicola; Mycosphaerella         fijiensis;     -   Phaeosphaeria diseases, caused for example by Phaeosphaeria         nodorum;     -   Pyrenophora diseases, caused for example by Pyrenophora teres;     -   Ramularia diseases, caused for example by Ramularia collo-cygni;     -   Rhynchosporium diseases, caused for example by Rhynchosporium         secalis;     -   Septoria diseases, caused for example by Septoria apii or         Septoria lycopercisi;     -   Typhula diseases, caused for example by Typhula incarnate;     -   Venturia diseases, caused for example by Venturia inaequalis; -   Root and stem diseases such as:     -   Corticium diseases, caused for example by Corticium graminearum;     -   Fusarium diseases, caused for example by Fusarium oxysporum;     -   Gaeumannomyces diseases, caused for example by Gaeumannomyces         graminis;     -   Rhizoctonia diseases, caused for example by Rhizoctonia solani;     -   Tapesia diseases, caused for example by Tapesia acuformis;     -   Thielaviopsis diseases, caused for example by Thielaviopsis         basicola; -   Ear and panicle diseases such as:     -   Alternaria diseases, caused for example by Alternaria spp.;     -   Aspergillus diseases, caused for example by Aspergillus flavus;     -   Cladosporium diseases, caused for example by Cladosporium spp.;     -   Claviceps diseases, caused for example by Claviceps purpurea;     -   Fusarium diseases, caused for example by Fusarium culmorum;     -   Gibberella diseases, caused for example by Gibberella zeae;     -   Monographella diseases, caused for example by Monographella         nivalis; -   Smut and bunt diseases such as:     -   Sphacelotheca diseases, caused for example by Sphacelotheca         reiliana;     -   Tilletia diseases, caused for example by Tilletia caries;     -   Urocystis diseases, caused for example by Urocystis occulta;     -   Ustilago diseases, caused for example by Ustilago nuda; -   Fruit rot and mould diseases such as:     -   Aspergillus diseases, caused for example by Aspergillus flavus;     -   Botrytis diseases, caused for example by Botrytis cinerea;     -   Penicillium diseases, caused for example by Penicillium         expansum;     -   Sclerotinia diseases, caused for example by Sclerotinia         sclerotiorum;     -   Verticilium diseases, caused for example by Verticilium         alboatrum; -   Seed and soilborne decay, mould, wilt, rot and damping-off diseases:     -   Alternaria diseases, caused for example by Alternaria         brassicicola     -   Aphanomyces diseases, caused for example by Aphanomyces         euteiches     -   Ascochyta diseases, caused for example by Ascochyta lentis     -   Aspergillus diseases, caused for example by Aspergillus flavus     -   Cladosporium diseases, caused for example by Cladosporium         herbarum     -   Cochliobolus diseases, caused for example by Cochliobolus         sativus     -   (Conidiaform: Drechslera, Bipolaris Syn: Helminthosporium);     -   Colletotrichum diseases, caused for example by Colletotrichum         coccodes;     -   Fusarium diseases, caused for example by Fusarium culmorum;     -   Gibberella diseases, caused for example by Gibberella zeae;     -   Macrophomina diseases, caused for example by Macrophomina         phaseolina     -   Monographella diseases, caused for example by Monographella         nivalis;     -   Penicillium diseases, caused for example by Penicillium expansum     -   Phoma diseases, caused for example by Phoma lingam     -   Phomopsis diseases, caused for example by Phomopsis sojae;     -   Phytophthora diseases, caused for example by Phytophthora         cactorum;     -   Pyrenophora diseases, caused for example by Pyrenophora graminea     -   Pyricularia diseases, caused for example by Pyricularia oryzae;     -   Pythium diseases, caused for example by Pythium ultimum;     -   Rhizoctonia diseases, caused for example by Rhizoctonia solani;     -   Rhizopus diseases, caused for example by Rhizopus oryzae     -   Sclerotium diseases, caused for example by Sclerotium rolfsii;     -   Septoria diseases, caused for example by Septoria nodorum;     -   Typhula diseases, caused for example by Typhula incarnate;     -   Verticillium diseases, caused for example by Verticillium         dahliae; -   Canker, broom and dieback diseases such as:     -   Nectria diseases, caused for example by Nectria galligena; -   Blight diseases such as:     -   Monilinia diseases, caused for example by Monilinia lexa; -   Leaf blister or leaf curl diseases such as:     -   Taphrina diseases, caused for example by Taphrina deformans; -   Decline diseases of wooden plants such as:     -   Esca diseases, caused for example by Phaemoniella clamydospora;     -   Eutypa dyeback, caused for example by Eutypa lata;     -   Dutch elm disease, caused for example by Ceratocystsc ulmi; -   Diseases of flowers and Seeds such as:     -   Botrytis diseases, caused for example by Botrytis cinerea; -   Diseases of tubers such as:     -   Rhizoctonia diseases, caused for example by Rhizoctonia solani     -   Helminthosporium diseases, caused for example by         Helminthosporium solani.

The compounds according to the invention can also be used for the preparation of composition useful to curatively or preventively treat human or animal fungal diseases such as, for example, mycoses, dermatoses, trichophyton diseases and candidiases or diseases caused by Aspergillus spp., for example Aspergillus fumigatus.

The present invention further relates to the use of compounds of the formula (I) as herein defined for the control of phytopathogenic fungi.

The present invention further relates to the use of compounds of the formula (I) as herein defined for the treatment of transgenic plants.

The present invention further relates to the use of compounds of the formula (I) as herein defined for the treatment of seed and of seed of transgenic plants.

The present invention further relates to a process for producing compositions for controlling phytopathogenic harmful fungi, characterized in that derivatives of the formula (I) as herein defined are mixed with extenders and/or surfactants.

The various aspects of the invention will now be illustrated with reference to the following table 1 of compound examples and the following preparation or efficacy examples.

The various aspects of the invention will now be illustrated with reference to the following Table 1 of compound examples and the following preparation or efficacy examples.

The following Table 1 illustrates in a non-limiting manner examples of compounds according to the invention.

In table 1, we use this following abbreviation for specified claimed elements “A¹, A²” of the generic structure (I) of the invention:

TABLE 1 Stereo Ex-no Y1 Y2 Y3 Y4 Y5 X1 X2 X3 A Z1 Z2 Z3 Z4 chemistry LogP 1 H H H H H Me O CO A1 (N-hydroxyethanimidoyl)amino H H H (Z) 1.29^([a]) 2 H H H H H Me CO O A1 (N-hydroxyethanimidoyl)amino H H H (Z) 1.86^([a]) 3 H H H H H Me CO O A1 [N-(cyclopropylmethoxy)ethanimidoyl]amino H H H (Z) 3.39^([a]) 4 H H H H H Me O CO A1 CCPh H H H (Z) 3.63^([a]) 5 H H H H H Me O CO A1 (N-butoxyethanimidoyl)amino H H H (Z) 3.35^([a]) 6 H H H H H Me O CO A1 cyclopropylethynyl H H H (Z) 3.02^([a]) 7 H H H H H Me CO O A1 (N-butoxyethanimidoyl)amino H H H (Z) 3.69^([a]) 8 H H H H H Me O CO A1 [N-(benzyloxy)ethanimidoyl]amino H H H (Z) 3.09^([a]) 9 H H H H H Me CO O A1 [N-(benzyloxy)ethanimidoyl]amino H H H (Z) 3.73^([a]) 10 H H H H H Me O CO A1 hex-1-yn-1-yl H H H (Z) 3.81^([a]) 11 H H H H H Me O CO A1 3,3-dimethylbut-1-yn-1-yl H H H (Z) 3.72^([a]) 12 H H H H H Me O CO A11 cyclopropylethynyl H (Z) 3.13^([a]) 13 H H H H H Me CO O A1 cyclopropylethynyl H H H (Z) 3.65^([a]) 14 H H H H H Me O CO A11 cyclohexylethynyl H (Z) 4.44^([a]) 15 H H H H H Me CO O A1 CCPh H H H (Z) 4.26^([a]) 16 H H H H H Me CO O A11 cyclohexylethynyl H (Z) 5.08^([a]) 17 H H H H H Me CO O A11 cyclopropylethynyl H (Z) 3.76^([a]) 18 H H H H H Me O CO A11 3-phenylprop-1-yn-1-yl H (Z) 3.74^([a]) 19 H H H H H Me CO O A11 3-phenylprop-1-yn-1-yl H (Z) 4.37^([a]) 20 H H H H H Me O CO A11 (1E)-3-phenylprop-1-en-1-yl H (Z) 3.85^([a]) 21 H H H H H Me CO O A1 (E)-2-cyclopropylvinyl H H H (Z) 3.48^([a]) 22 H H H H H Me O CO A11 (E)-2-cyclohexylvinyl H (Z) 4.64^([a]) 23 H H H H H Me CO O A1 Styryl H H H (Z) 4.37^([a])

Measurement of log P values was performed according EEC directive 79/831 Annex V.A8 by HPLC (High Performance Liquid Chromatography) on reversed phase columns with the following methods: ^([a])Measurement of LC-MS was done at pH 2.7 with 0.1% formic acid in water and with acetonitrile (contains 0.1% formic acid) as eluent with a linear gradient from 10% acetonitrile to 95% acetonitrile. Calibration was done with not branched alkan2-ones (with 3 to 16 carbon atoms) with known log P-values (measurement of log P values using retention times with linear interpolation between successive alkanones). lambda-maX-values were determined using UV-spectra from 200 nm to 400 nm and the peak values of the chromatographic signals.

NMR Peak Lists

1H-NMR data of selected examples are written in form of 1H-NMR-peak lists. To each signal peak are listed the δ-value in ppm and the signal intensity in round brackets. Between the δ-value—signal intensity pairs are semicolons as delimiters.

The peak list of an example has therefore the form:

δ₁ (intensity₁); δ₂ (intensity₂); . . . ; δ_(i) (intensity_(i)); . . . ; δ_(n) (intensity_(n))

NMR Peak Lists Table 1 Example 1: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 8.781 (0.4); 8.637 (2.0); 7.792 (0.9); 7.772 (1.0); 7.699 (0.7); 7.680 (1.3); 7.666 (4.8); 7.663 (4.6); 7.657 (3.8); 7.648 (5.4); 7.645 (5.7); 7.638 (4.1); 7.617 (1.7); 7.594 (0.4); 7.589 (0.5); 7.580 (0.7); 7.569 (1.2); 7.551 (2.9); 7.545 (1.3); 7.533 (3.4); 7.510 (5.2); 7.491 (6.7); 7.472 (3.1); 7.454 (0.9); 7.433 (0.4); 7.388 (0.5); 7.075 (2.1); 7.055 (2.0); 6.901 (2.2); 6.883 (2.2); 6.870 (0.9); 6.611 (0.7); 6.593 (0.7); 6.509 (0.8); 6.489 (0.7); 6.441 (0.5); 6.421 (0.5); 5.330 (1.1); 5.316 (7.4); 5.305 (3.2); 5.247 (3.0); 5.201 (0.4); 5.143 (0.9); 3.705 (1.6); 3.698 (0.8); 3.683 (6.8); 3.669 (16.0); 3.132 (0.4); 3.076 (1.0); 2.549 (0.7); 2.512 (41.4); 2.508 (53.2); 2.503 (39.9); 2.400 (0.4); 2.330 (0.8); 2.207 (14.9); 2.079 (0.9); 2.017 (5.3); 1.470 (0.5); 1.260 (1.0); 1.244 (1.0) Example 2: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 8.770 (0.9); 8.626 (0.7); 7.798 (0.6); 7.777 (0.9); 7.739 (3.1); 7.735 (2.5); 7.727 (1.6); 7.721 (3.8); 7.717 (3.1); 7.695 (0.7); 7.677 (0.8); 7.653 (1.4); 7.634 (1.9); 7.633 (1.9); 7.614 (1.6); 7.568 (0.8); 7.565 (0.6); 7.557 (0.6); 7.550 (2.4); 7.544 (1.0); 7.535 (1.5); 7.532 (2.3); 7.505 (3.6); 7.486 (4.4); 7.469 (1.9); 7.454 (0.3); 7.076 (2.0); 7.056 (1.9); 6.899 (2.0); 6.882 (2.2); 6.867 (0.8); 5.998 (0.4); 5.322 (6.9); 5.305 (2.8); 5.185 (0.9); 3.318 (5.7); 3.093 (2.0); 3.073 (0.7); 3.059 (6.3); 3.042 (16.0); 3.026 (0.5); 2.719 (0.5); 2.517 (15.0); 2.512 (28.3); 2.508 (37.2); 2.503 (26.7); 2.499 (13.2); 2.209 (0.9); 2.197 (15.0); 2.180 (0.5); 2.013 (5.5); 1.995 (1.3); 1.543 (1.0); 1.199 (0.4); 1.181 (0.6) Example 3: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.812 (1.2); 7.726 (0.3); 7.665 (1.9); 7.660 (2.3); 7.655 (1.6); 7.650 (1.1); 7.645 (1.3); 7.638 (2.9); 7.633 (2.5); 7.622 (0.8); 7.604 (1.2); 7.578 (1.8); 7.552 (1.4); 7.507 (0.4); 7.495 (0.4); 7.482 (1.3); 7.473 (0.6); 7.464 (1.4); 7.459 (1.9); 7.453 (1.5); 7.445 (3.0); 7.420 (3.0); 7.403 (0.6); 7.398 (1.0); 7.391 (0.7); 7.263 (8.1); 6.906 (1.8); 6.881 (1.7); 6.727 (1.7); 6.700 (1.6); 5.321 (6.9); 5.304 (1.5); 5.278 (0.7); 3.845 (4.1); 3.834 (0.7); 3.821 (4.2); 3.811 (0.6); 3.114 (16.0); 3.098 (1.2); 3.093 (3.1); 3.084 (1.5); 2.715 (0.4); 2.334 (14.7); 2.323 (0.8); 2.219 (2.5); 2.146 (0.5); 1.628 (0.7); 1.255 (0.8); 1.215 (0.5); 1.212 (0.5); 1.204 (0.5); 1.199 (0.4); 1.188 (0.8); 1.177 (0.4); 1.172 (0.5); 1.164 (0.5); 1.162 (0.5); 0.597 (0.5); 0.582 (1.7); 0.577 (2.0); 0.562 (1.0); 0.555 (1.9); 0.550 (1.7); 0.535 (0.7); 0.316 (0.7); 0.301 (2.3); 0.285 (2.0); 0.281 (2.1); 0.266 (0.5); 0.000 (4.9) Example 4: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.944 (1.3); 7.925 (2.7); 7.905 (1.6); 7.663 (2.8); 7.650 (1.1); 7.645 (3.9); 7.641 (3.2); 7.635 (3.9); 7.631 (2.9); 7.623 (2.0); 7.617 (3.3); 7.614 (2.9); 7.611 (2.9); 7.573 (0.4); 7.570 (0.6); 7.567 (0.4); 7.558 (0.5); 7.551 (1.7); 7.546 (0.6); 7.537 (1.1); 7.533 (1.6); 7.530 (0.9); 7.506 (2.9); 7.487 (4.4); 7.481 (5.5); 7.477 (5.0); 7.470 (3.3); 7.464 (4.4); 7.455 (0.9); 7.452 (0.9); 7.444 (2.0); 7.366 (0.4); 5.479 (6.7); 3.779 (16.0); 3.382 (0.3); 3.335 (39.1); 3.289 (0.4); 2.550 (0.3); 2.512 (10.5); 2.508 (20.7); 2.503 (27.5); 2.499 (19.7); 2.495 (9.4); 2.458 (0.3); 1.990 (1.2); 1.244 (0.8); 1.193 (0.3); 1.175 (0.6); 0.874 (0.4); 0.858 (1.1); 0.840 (0.4); 0.000 (1.1) Example 5: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.741 (1.1); 7.653 (1.5); 7.649 (2.2); 7.643 (1.5); 7.634 (0.8); 7.626 (2.6); 7.621 (2.5); 7.606 (1.2); 7.580 (1.6); 7.554 (1.2); 7.499 (0.4); 7.474 (1.2); 7.466 (0.5); 7.457 (1.0); 7.452 (1.6); 7.446 (1.0); 7.435 (2.6); 7.430 (1.3); 7.417 (1.1); 7.415 (1.2); 7.410 (2.5); 7.393 (0.5); 7.387 (0.9); 7.381 (0.6); 7.266 (5.9); 6.922 (1.5); 6.898 (1.4); 6.709 (1.5); 6.682 (1.4); 5.311 (6.2); 5.290 (0.7); 5.272 (0.6); 4.049 (2.1); 4.026 (4.3); 4.010 (0.6); 4.004 (2.2); 3.592 (16.0); 3.582 (2.4); 3.563 (1.5); 2.327 (14.4); 2.218 (0.5); 2.108 (1.3); 1.722 (0.6); 1.698 (1.5); 1.690 (0.7); 1.676 (1.6); 1.668 (1.1); 1.650 (1.5); 1.627 (0.7); 1.450 (0.9); 1.431 (0.7); 1.425 (1.3); 1.407 (0.7); 1.399 (1.4); 1.383 (0.4); 1.375 (0.9); 1.320 (1.3); 1.300 (1.3); 1.253 (0.6); 0.978 (3.6); 0.953 (7.3); 0.929 (2.9); 0.072 (6.7); 0.000 (3.7) Example 6: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.831 (1.3); 7.811 (2.8); 7.792 (1.6); 7.649 (2.8); 7.632 (3.6); 7.628 (2.7); 7.571 (0.6); 7.567 (0.4); 7.559 (0.5); 7.552 (1.8); 7.547 (0.6); 7.537 (1.1); 7.534 (1.5); 7.506 (2.8); 7.490 (2.1); 7.487 (3.4); 7.473 (0.8); 7.469 (1.4); 7.466 (1.1); 7.453 (0.4); 7.398 (2.0); 7.379 (1.8); 7.359 (2.0); 7.340 (1.8); 5.404 (7.1); 3.743 (16.0); 3.725 (0.4); 3.410 (1.5); 3.407 (2.3); 3.366 (241.3); 3.326 (1.7); 3.322 (1.9); 2.553 (0.3); 2.549 (0.4); 2.516 (10.4); 2.512 (20.4); 2.508 (26.9); 2.504 (19.5); 2.468 (0.3); 2.464 (0.3); 1.603 (0.7); 1.594 (0.7); 1.590 (0.5); 1.582 (1.3); 1.574 (0.5); 1.570 (0.8); 1.561 (0.7); 1.549 (0.4); 1.249 (0.8); 0.955 (0.7); 0.944 (1.9); 0.937 (2.5); 0.928 (1.3); 0.923 (2.0); 0.916 (2.2); 0.907 (0.9); 0.878 (0.4); 0.871 (0.3); 0.861 (1.0); 0.844 (0.4); 0.802 (1.0); 0.793 (2.5); 0.789 (1.6); 0.787 (2.3); 0.781 (2.4); 0.774 (2.2); 0.763 (0.7) Example 7: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 8.978 (0.6); 8.618 (2.4); 7.874 (0.4); 7.853 (0.5); 7.747 (0.6); 7.738 (2.7); 7.734 (1.8); 7.726 (1.2); 7.720 (3.5); 7.716 (2.7); 7.711 (0.9); 7.687 (1.3); 7.668 (1.7); 7.667 (1.8); 7.648 (1.5); 7.569 (0.6); 7.566 (0.4); 7.557 (0.4); 7.551 (2.0); 7.545 (0.6); 7.536 (1.1); 7.533 (1.8); 7.529 (0.9); 7.504 (2.9); 7.489 (1.9); 7.485 (3.5); 7.472 (0.6); 7.468 (1.4); 7.096 (1.8); 7.076 (1.7); 6.946 (1.8); 6.928 (1.9); 6.913 (0.4); 5.332 (6.3); 5.316 (1.5); 3.927 (2.3); 3.910 (5.0); 3.893 (2.6); 3.336 (23.2); 3.056 (3.9); 3.042 (16.0); 2.530 (0.5); 2.517 (11.8); 2.512 (24.3); 2.508 (32.8); 2.503 (23.4); 2.499 (10.9); 2.184 (0.5); 2.172 (14.6); 2.032 (3.4); 1.644 (0.5); 1.627 (1.4); 1.620 (0.6); 1.609 (1.8); 1.590 (1.7); 1.573 (0.7); 1.401 (0.3); 1.390 (0.4); 1.382 (1.1); 1.368 (1.0); 1.363 (1.8); 1.349 (1.0); 1.344 (1.8); 1.334 (0.4); 1.331 (0.5); 1.326 (1.1); 0.926 (1.4); 0.921 (4.2); 0.907 (2.7); 0.903 (8.5); 0.889 (1.3); 0.884 (3.6); −0.057 (0.6) Example 8: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 9.011 (0.6); 8.824 (2.5); 7.793 (0.4); 7.695 (1.6); 7.674 (2.0); 7.658 (3.0); 7.655 (3.1); 7.646 (0.9); 7.641 (3.6); 7.637 (3.1); 7.568 (0.5); 7.565 (0.3); 7.557 (0.4); 7.550 (1.8); 7.544 (0.5); 7.535 (1.1); 7.532 (1.6); 7.528 (0.8); 7.506 (3.1); 7.491 (1.9); 7.487 (3.5); 7.474 (0.6); 7.470 (1.4); 7.466 (0.8); 7.408 (1.1); 7.404 (1.6); 7.387 (3.9); 7.372 (2.4); 7.367 (0.8); 7.362 (1.0); 7.355 (3.4); 7.350 (1.3); 7.335 (1.4); 7.307 (0.8); 7.303 (1.2); 7.299 (0.7); 7.292 (0.7); 7.286 (1.3); 7.279 (0.4); 7.268 (0.4); 7.125 (1.8); 7.105 (1.7); 6.954 (1.8); 6.935 (1.8); 6.926 (0.4); 6.908 (0.4); 5.766 (6.3); 5.324 (6.1); 5.307 (1.3); 4.997 (6.6); 4.965 (1.5); 3.675 (3.4); 3.658 (16.0); 3.336 (38.5); 2.677 (0.4); 2.530 (1.0); 2.517 (21.8); 2.512 (44.6); 2.508 (60.1); 2.503 (42.5); 2.499 (19.7); 2.462 (0.4); 2.458 (0.4); 2.335 (0.4); 2.168 (14.3); 2.082 (0.7); 2.069 (3.0); −0.058 (0.7) Example 9: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 9.025 (0.7); 8.829 (2.5); 7.815 (0.4); 7.794 (0.6); 7.736 (2.0); 7.733 (2.8); 7.729 (2.0); 7.721 (1.0); 7.716 (3.7); 7.712 (3.3); 7.707 (1.1); 7.695 (1.7); 7.676 (1.8); 7.674 (2.0); 7.655 (1.5); 7.567 (0.6); 7.564 (0.4); 7.555 (0.5); 7.549 (1.9); 7.543 (0.7); 7.534 (1.1); 7.531 (1.8); 7.527 (1.0); 7.502 (3.0); 7.487 (2.1); 7.483 (3.8); 7.469 (0.8); 7.465 (1.6); 7.462 (1.1); 7.406 (1.3); 7.402 (1.6); 7.385 (4.2); 7.382 (3.6); 7.373 (2.1); 7.371 (2.6); 7.365 (1.2); 7.362 (1.4); 7.353 (3.6); 7.349 (1.6); 7.344 (0.7); 7.342 (0.7); 7.338 (1.1); 7.334 (1.5); 7.314 (0.3); 7.310 (0.5); 7.305 (0.9); 7.301 (1.2); 7.297 (0.8); 7.290 (0.7); 7.283 (1.3); 7.277 (0.5); 7.270 (0.4); 7.266 (0.5); 7.129 (1.8); 7.108 (1.7); 6.957 (1.8); 6.938 (1.7); 6.928 (0.6); 6.911 (0.5); 5.766 (5.0); 5.332 (6.1); 5.310 (1.7); 4.997 (6.6); 4.965 (1.9); 3.337 (29.2); 3.058 (0.6); 3.049 (4.1); 3.031 (16.0); 2.713 (0.3); 2.531 (0.7); 2.526 (1.1); 2.517 (14.2); 2.513 (30.1); 2.508 (41.8); 2.504 (31.3); 2.499 (16.1); 2.173 (0.5); 2.160 (14.1); 2.091 (0.4); 2.070 (3.6); −0.057 (1.2) Example 10: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.841 (1.3); 7.822 (2.7); 7.802 (1.5); 7.653 (1.9); 7.650 (2.6); 7.646 (1.5); 7.638 (1.0); 7.633 (3.6); 7.629 (2.8); 7.570 (0.3); 7.567 (0.6); 7.563 (0.4); 7.555 (0.5); 7.548 (1.7); 7.543 (0.7); 7.534 (1.0); 7.530 (1.6); 7.527 (0.9); 7.501 (2.6); 7.498 (1.4); 7.486 (2.0); 7.482 (3.4); 7.469 (1.0); 7.465 (1.6); 7.462 (1.1); 7.450 (0.3); 7.413 (1.8); 7.393 (1.6); 7.374 (1.7); 7.354 (1.6); 5.417 (6.4); 3.746 (16.0); 3.721 (0.3); 3.379 (0.4); 3.335 (49.2); 3.291 (0.5); 2.525 (0.4); 2.512 (9.1); 2.508 (19.1); 2.503 (26.4); 2.499 (19.9); 2.494 (10.3); 2.471 (2.5); 2.453 (4.5); 2.436 (2.3); 1.570 (0.3); 1.555 (1.1); 1.547 (0.6); 1.537 (1.6); 1.535 (1.7); 1.530 (1.1); 1.517 (1.6); 1.500 (0.7); 1.470 (0.4); 1.452 (1.1); 1.440 (0.8); 1.434 (1.6); 1.422 (0.8); 1.415 (1.6); 1.404 (0.4); 1.397 (0.9); 1.246 (0.5); 0.926 (4.1); 0.919 (0.6); 0.908 (8.2); 0.890 (3.5); 0.875 (0.4); 0.858 (0.7); 0.840 (0.3); 0.000 (1.9) Example 11: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.841 (0.4); 7.822 (0.9); 7.803 (0.5); 7.654 (0.8); 7.650 (0.4); 7.636 (1.1); 7.633 (0.8); 7.554 (0.5); 7.536 (0.5); 7.507 (0.8); 7.492 (0.5); 7.488 (1.0); 7.471 (0.4); 7.392 (0.6); 7.373 (1.1); 7.354 (0.6); 5.427 (2.1); 3.765 (5.1); 3.341 (11.6); 2.517 (2.8); 2.513 (5.7); 2.508 (7.8); 2.504 (5.6); 2.499 (2.6); 1.314 (0.6); 1.304 (16.0); 0.863 (0.4) Example 12: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.784 (4.6); 7.670 (2.7); 7.666 (1.5); 7.658 (1.0); 7.653 (3.5); 7.649 (2.7); 7.576 (0.5); 7.573 (0.4); 7.565 (0.4); 7.558 (1.7); 7.552 (0.6); 7.543 (1.0); 7.540 (1.6); 7.536 (0.9); 7.515 (2.7); 7.500 (1.8); 7.496 (3.1); 7.483 (0.7); 7.479 (1.3); 7.475 (0.8); 5.407 (6.7); 3.653 (16.0); 3.340 (58.6); 2.531 (0.6); 2.517 (10.3); 2.513 (20.8); 2.508 (28.2); 2.504 (21.2); 2.500 (11.1); 1.678 (0.7); 1.670 (0.7); 1.666 (0.5); 1.658 (1.3); 1.650 (0.5); 1.645 (0.8); 1.637 (0.8); 1.625 (0.4); 1.251 (0.4); 1.001 (0.6); 0.990 (1.7); 0.983 (2.4); 0.974 (1.2); 0.969 (1.9); 0.962 (2.2); 0.953 (1.0); 0.867 (1.1); 0.864 (0.8); 0.858 (2.5); 0.854 (1.6); 0.851 (2.2); 0.846 (2.6); 0.839 (2.2); 0.828 (0.7) Example 13: ¹H-NMR (499.9 MHz, CDCl₃): δ = 7.655 (1.3); 7.642 (3.5); 7.639 (4.2); 7.628 (3.6); 7.625 (3.5); 7.497 (0.7); 7.483 (1.7); 7.468 (1.5); 7.437 (2.5); 7.422 (3.2); 7.408 (1.3); 7.314 (1.9); 7.298 (1.8); 7.267 (38.8); 7.223 (1.8); 7.207 (1.7); 5.432 (7.9); 3.337 (0.6); 3.142 (16.0); 2.965 (0.7); 2.890 (0.6); 2.291 (0.3); 1.613 (10.6); 1.519 (0.6); 1.508 (0.8); 1.503 (0.9); 1.499 (0.7); 1.492 (1.4); 1.487 (0.7); 1.481 (0.8); 1.476 (0.8); 1.466 (0.5); 1.251 (1.6); 0.925 (1.3); 0.920 (2.9); 0.916 (2.0); 0.908 (3.0); 0.904 (5.2); 0.901 (3.9); 0.897 (3.1); 0.895 (3.6); 0.890 (1.7); 0.875 (0.4); 0.841 (0.3); 0.070 (1.3); 0.006 (1.1); 0.000 (24.5) Example 14: ¹H-NMR (300.2 MHz, d₆-DMSO): δ = 7.799 (2.6); 7.674 (1.0); 7.669 (1.3); 7.664 (0.7); 7.647 (1.7); 7.642 (1.4); 7.554 (0.8); 7.536 (0.6); 7.531 (1.0); 7.525 (0.5); 7.514 (1.6); 7.496 (0.7); 7.489 (1.5); 7.467 (0.5); 5.414 (3.4); 3.655 (9.0); 3.321 (16.0); 2.739 (0.4); 2.726 (0.3); 2.513 (3.0); 2.507 (6.6); 2.501 (9.2); 2.495 (6.8); 2.489 (3.3); 1.989 (1.2); 1.858 (0.4); 1.838 (0.4); 1.817 (0.5); 1.666 (0.5); 1.646 (0.5); 1.636 (0.5); 1.507 (0.7); 1.491 (0.6); 1.474 (0.6); 1.372 (0.5); 1.341 (1.1); 1.313 (0.6); 1.246 (0.5); 1.198 (0.4); 1.174 (0.7); 1.151 (0.4); 0.858 (0.5); 0.000 (9.7); −0.011 (0.4) Example 15: ¹H-NMR (300.2 MHz, d₆-DMSO): δ = 7.949 (0.4); 7.923 (0.9); 7.897 (0.6); 7.737 (0.9); 7.714 (1.1); 7.708 (0.8); 7.637 (1.3); 7.630 (0.9); 7.619 (0.9); 7.614 (1.1); 7.605 (1.0); 7.551 (0.5); 7.528 (0.6); 7.523 (0.4); 7.505 (1.0); 7.484 (2.3); 7.478 (2.5); 7.467 (1.8); 7.443 (0.8); 5.481 (2.2); 3.322 (16.0); 3.148 (5.1); 2.513 (2.6); 2.507 (5.4); 2.501 (7.4); 2.495 (5.5); 2.490 (2.8); 0.000 (6.4) Example 16: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.664 (1.6); 7.659 (2.1); 7.654 (1.1); 7.644 (0.8); 7.637 (2.6); 7.631 (2.2); 7.507 (0.3); 7.482 (1.1); 7.473 (0.5); 7.464 (1.0); 7.459 (1.6); 7.453 (1.1); 7.444 (2.5); 7.440 (1.2); 7.427 (1.1); 7.424 (1.2); 7.420 (2.3); 7.403 (0.5); 7.397 (0.8); 7.391 (0.5); 7.266 (3.2); 7.233 (3.4); 5.4244 (6.1); 5.4235 (6.1); 3.100 (0.4); 3.087 (16.0); 2.669 (0.3); 2.651 (0.4); 2.638 (0.7); 2.625 (0.5); 2.607 (0.4); 1.912 (0.6); 1.897 (0.7); 1.877 (0.8); 1.868 (0.8); 1.773 (0.6); 1.760 (0.9); 1.742 (1.0); 1.729 (0.7); 1.638 (0.8); 1.623 (0.5); 1.611 (0.5); 1.590 (0.8); 1.579 (0.9); 1.561 (1.1); 1.547 (1.2); 1.515 (0.6); 1.387 (0.7); 1.380 (0.8); 1.355 (1.4); 1.346 (1.4); 1.313 (0.6); 1.266 (0.6); 1.259 (0.6); 0.881 (0.5); 0.000 (0.8) Example 17: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.662 (1.6); 7.657 (2.0); 7.652 (1.0); 7.642 (0.8); 7.635 (2.5); 7.629 (2.1); 7.481 (1.1); 7.472 (0.5); 7.463 (1.0); 7.458 (1.6); 7.452 (1.0); 7.443 (2.4); 7.438 (1.1); 7.425 (1.1); 7.423 (1.1); 7.419 (2.4); 7.402 (0.5); 7.396 (0.9); 7.389 (0.8); 7.266 (2.9); 7.219 (3.5); 5.411 (6.8); 3.077 (16.0); 2.045 (0.4); 1.632 (1.2); 1.522 (0.4); 1.520 (0.4); 1.512 (0.6); 1.505 (0.4); 1.495 (1.0); 1.486 (0.4); 1.478 (0.4); 1.475 (0.5); 1.468 (0.6); 1.450 (0.4); 1.259 (0.6); 0.970 (0.9); 0.961 (1.9); 0.960 (1.9); 0.954 (1.2); 0.942 (1.2); 0.937 (2.3); 0.933 (3.8); 0.928 (2.7); 0.920 (1.8); 0.914 (2.5); 0.905 (1.2); 0.901 (0.6); 0.882 (0.6); 0.000 (0.8) Example 18: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.654 (1.6); 7.649 (2.0); 7.644 (1.1); 7.634 (0.8); 7.627 (2.6); 7.621 (2.1); 7.500 (0.3); 7.476 (1.2); 7.467 (0.5); 7.458 (1.0); 7.452 (1.5); 7.447 (0.9); 7.443 (0.7); 7.435 (2.4); 7.430 (1.1); 7.417 (1.2); 7.415 (1.2); 7.411 (2.4); 7.398 (0.6); 7.388 (1.3); 7.381 (0.9); 7.369 (4.1); 7.366 (4.1); 7.347 (2.2); 7.344 (2.8); 7.337 (0.8); 7.325 (0.6); 7.320 (0.8); 7.318 (0.9); 7.302 (3.7); 7.291 (0.9); 7.282 (0.5); 7.280 (0.6); 7.262 (8.3); 7.248 (0.4); 5.422 (6.1); 5.421 (6.0); 3.877 (6.0); 3.571 (16.0); 3.549 (0.3); 2.005 (0.4); 1.666 (0.4); 0.000 (2.2) Example 19: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.664 (1.6); 7.660 (2.0); 7.654 (1.1); 7.645 (0.9); 7.637 (2.5); 7.632 (2.1); 7.509 (0.4); 7.484 (1.1); 7.475 (0.6); 7.466 (1.1); 7.461 (1.7); 7.455 (1.2); 7.446 (2.5); 7.441 (1.2); 7.428 (1.2); 7.426 (1.3); 7.421 (2.4); 7.399 (1.2); 7.392 (1.1); 7.370 (3.7); 7.367 (4.2); 7.348 (2.1); 7.345 (2.7); 7.339 (0.8); 7.326 (0.7); 7.321 (0.8); 7.320 (0.9); 7.296 (0.7); 7.289 (0.9); 7.282 (0.6); 7.270 (4.5); 7.261 (22.1); 7.252 (0.7); 7.246 (0.5); 7.240 (0.4); 5.436 (6.0); 5.435 (5.7); 3.880 (5.6); 3.101 (0.5); 3.089 (16.0); 3.071 (0.5); 1.607 (1.1); 0.000 (5.7) Example 20: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.667 (2.5); 7.663 (1.3); 7.655 (0.9); 7.649 (3.4); 7.646 (2.5); 7.632 (3.7); 7.569 (0.5); 7.566 (0.3); 7.558 (0.4); 7.550 (1.6); 7.545 (0.5); 7.536 (1.0); 7.532 (1.5); 7.529 (0.8); 7.507 (2.5); 7.492 (1.6); 7.488 (3.0); 7.475 (0.5); 7.471 (1.2); 7.467 (0.7); 7.351 (1.1); 7.347 (0.5); 7.333 (2.7); 7.319 (1.0); 7.315 (2.6); 7.273 (3.4); 7.256 (2.6); 7.235 (1.4); 7.230 (0.4); 7.221 (0.4); 7.217 (0.5); 6.731 (1.0); 6.717 (2.6); 6.710 (3.6); 6.708 (3.0); 6.671 (0.4); 5.394 (6.5); 4.045 (0.8); 4.028 (0.8); 3.651 (16.0); 3.582 (2.8); 3.569 (2.8); 3.316 (6.6); 2.530 (0.5); 2.516 (9.9); 2.512 (19.9); 2.508 (26.6); 2.503 (18.8); 2.499 (8.9); 1.995 (3.5); 1.254 (0.3); 1.199 (1.0); 1.182 (1.9); 1.164 (0.9); 0.865 (0.5) Example 21: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.760 (1.2); 7.741 (2.8); 7.733 (2.7); 7.722 (1.9); 7.715 (3.3); 7.711 (2.4); 7.569 (0.5); 7.557 (0.4); 7.550 (1.6); 7.545 (0.5); 7.535 (0.9); 7.532 (1.4); 7.529 (0.7); 7.502 (2.4); 7.487 (1.7); 7.483 (3.1); 7.469 (0.5); 7.465 (1.2); 7.462 (0.7); 7.282 (1.7); 7.263 (1.6); 7.204 (1.7); 7.186 (1.6); 6.583 (1.9); 6.545 (2.5); 6.309 (1.3); 6.285 (1.3); 6.271 (1.0); 6.247 (1.0); 5.405 (6.9); 4.045 (0.4); 4.027 (0.4); 3.315 (6.2); 3.131 (0.4); 3.081 (16.0); 2.516 (10.7); 2.512 (21.1); 2.507 (28.1); 2.503 (19.9); 2.499 (9.4); 1.995 (1.6); 1.659 (0.3); 1.651 (0.6); 1.639 (0.6); 1.627 (0.6); 1.618 (0.4); 1.615 (0.3); 1.199 (0.4); 1.181 (0.8); 1.164 (0.4); 0.873 (0.6); 0.862 (1.8); 0.857 (1.9); 0.847 (1.1); 0.842 (1.7); 0.837 (1.7); 0.827 (0.6); 0.570 (0.7); 0.560 (2.0); 0.555 (1.9); 0.549 (1.9); 0.543 (2.1); 0.532 (0.6) Example 22: ¹H-NMR (400.1 MHz, d₆-DMSO): δ = 7.674 (1.8); 7.671 (2.4); 7.667 (1.2); 7.659 (0.8); 7.654 (3.3); 7.650 (2.3); 7.609 (3.6); 7.572 (0.4); 7.561 (0.4); 7.554 (1.5); 7.548 (0.5); 7.539 (0.9); 7.536 (1.5); 7.532 (0.7); 7.513 (2.5); 7.509 (1.1); 7.498 (1.6); 7.494 (2.8); 7.481 (0.5); 7.476 (1.1); 7.473 (0.6); 6.624 (0.5); 6.584 (4.1); 6.579 (2.6); 6.565 (2.0); 6.525 (0.4); 5.394 (6.2); 3.668 (16.0); 3.315 (13.3); 3.270 (0.5); 2.530 (0.6); 2.525 (1.0); 2.516 (14.9); 2.512 (30.6); 2.507 (41.5); 2.503 (29.2); 2.499 (13.6); 2.199 (0.3); 2.191 (0.5); 2.178 (0.5); 1.784 (0.9); 1.747 (1.5); 1.729 (0.7); 1.713 (0.9); 1.705 (1.1); 1.659 (0.5); 1.628 (0.5); 1.310 (0.8); 1.286 (0.8); 1.279 (1.2); 1.255 (0.9); 1.248 (1.1); 1.211 (0.9); 1.181 (1.6); 1.149 (1.2); 1.125 (0.4); 0.865 (0.7) Example 23: ¹H-NMR (300.2 MHz, CDCl₃): δ = 7.715 (1.0); 7.690 (2.2); 7.678 (1.7); 7.674 (2.1); 7.668 (1.3); 7.664 (1.6); 7.659 (1.0); 7.652 (3.8); 7.646 (2.5); 7.597 (1.9); 7.585 (1.5); 7.580 (2.0); 7.556 (2.4); 7.505 (0.3); 7.480 (1.0); 7.471 (0.5); 7.462 (1.0); 7.457 (1.6); 7.451 (1.2); 7.443 (2.5); 7.439 (1.1); 7.426 (1.1); 7.423 (1.2); 7.419 (2.4); 7.408 (1.0); 7.403 (1.4); 7.397 (1.2); 7.389 (0.9); 7.380 (2.5); 7.374 (1.4); 7.366 (1.7); 7.355 (1.8); 7.341 (1.4); 7.331 (0.9); 7.327 (1.3); 7.322 (0.8); 7.311 (0.5); 7.303 (1.3); 7.293 (0.3); 7.279 (0.5); 7.259 (10.4); 7.204 (1.5); 7.188 (2.4); 7.179 (1.4); 7.135 (1.8); 5.481 (6.6); 3.175 (0.7); 3.137 (16.0); 2.045 (0.4); 1.567 (2.4); 1.259 (0.9); 0.882 (0.7); 0.071 (0.7); 0.000 (2.5)

Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.

For calibrating chemical shift for 1H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily.

The 1H-NMR peak lists are similar to classical 1H-NMR prints and contain therefore usually all peaks, which are listed at classical NMR-interpretation.

Additionally they can show like classical 1H-NMR prints signals of solvents, stereoisomers of the target compounds, which are also object of the invention, and/or peaks of impurities.

To show compound signals in the delta-range of solvents and/or water the usual peaks of solvents, for example peaks of DMSO in DMSO-D₆ and the peak of water are shown in our 1H-NMR peak lists and have usually on average a high intensity.

The peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity>90%).

Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via “side-products-fingerprints”.

An expert, who calculates the peaks of the target compounds with known methods (MestreC, ACD-simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1H-NMR interpretation.

Further details of NMR-data description with peak lists you find in the publication “Citation of NMR Peaklist Data within Patent Applications” of the Research Disclosure Database Number 564025.

In table 2, we use this following abbreviation for specified claimed element “A¹” of the generic structure (IV) of the invention:

TABLE 2 Ex- Stereo no Y¹ Y² Y³ Y⁴ Y⁵ A Z¹ Z² Z³ Z⁴ chemistry LogP IV-1 H H H H H A¹ 4-[(2E)-2-hexylidenehydrazino] H H H (Z) 4.01^([a])

Measurement of log P values was performed according EEC directive 79/831 Annex V.A8 by HPLC (High Performance Liquid Chromatography) on reversed phase columns with the following methods: ^([a])Measurement of LC-MS was done at pH 2.7 with 0.1% formic acid in water and with acetonitrile (contains 0.1% formic acid) as eluent with a linear gradient from 10% acetonitrile to 95% acetonitrile. Calibration was done with not branched alkan2-ones (with 3 to 16 carbon atoms) with known log P-values (measurement of log P values using retention times with linear interpolation between successive alkanones). lambda-maX-values were determined using UV-spectra from 200 nm to 400 nm and the peak values of the chromatographic signals.

NMR Peak Lists

1H-NMR data of selected examples are written in form of 1H-NM R-peak lists. To each signal peak are listed the δ-value in ppm and the signal intensity in round brackets. Between the δ-value—signal intensity pairs are semicolons as delimiters.

The peak list of an example has therefore the form:

δ₁ (intensity₁); δ₂ (intensity₂); . . . ; δ_(i) (intensity_(i)); . . . ; δ_(n) (intensity_(n))

NMR Peak Lists Table 2 Example IV-1, Solvent: DMSO, Spectrometer: 400, 13 MHz 13.8018 (1.44); 10.4810 (6.56); 9.7798 (1.50); 7.7433 (9.57); 7.7263 (10.95); 7.6706 (0.71); 7.6510 (1.17); 7.6268 (2.58); 7.6066 (5.23); 7.5876 (6.16); 7.5652 (11.09); 7.5465 (12.57); 7.5318 (5.90); 7.3450 (2.27); 7.3317 (4.53); 7.3184 (2.42); 7.0922 (1.10); 7.0712 (1.05); 6.9923 (4.53); 6.9714 (4.34); 6.8667 (1.07); 6.8485 (1.05); 6.7829 (4.46); 6.7648 (4.36); 6.5251 (0.56); 6.5120 (1.14); 6.4986 (0.60); 5.5325 (0.89); 5.3835 (3.96); 5.3457 (16.00); 5.3129 (0.45); 4.0445 (0.45); 4.0268 (0.43); 3.3444 (11.84); 2.5115 (29.52); 2.3594 (0.60); 2.3415 (1.47); 2.3274 (1.36); 2.3094 (0.66); 2.2367 (2.11); 2.2192 (4.96); 2.2040 (4.95); 2.1866 (2.59); 1.9965 (1.69); 1.4908 (3.62); 1.4740 (5.10); 1.4568 (3.74); 1.3059 (11.10); 1.2978 (12.03); 1.2449 (6.88); 1.1994 (0.86); 1.1816 (1.09); 1.1637 (0.61); 0.9236 (0.63); 0.8765 (15.93); 0.8613 (11.27); 0.8442 (3.80)

Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.

For calibrating chemical shift for 1H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NMR peak lists, tetramethylsilane peak can occur but not necessarily.

The 1H-NMR peak lists are similar to classical 1H-NMR prints and contain therefore usually all peaks, which are listed at classical NMR-interpretation.

Additionally they can show like classical 1H-NMR prints signals of solvents, stereoisomers of the target compounds, which are also object of the invention, and/or peaks of impurities.

To show compound signals in the delta-range of solvents and/or water the usual peaks of solvents, for example peaks of DMSO in DMSO-D₆ and the peak of water are shown in our 1H-NMR peak lists and have usually on average a high intensity.

The peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity>90%).

Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via “side-products-fingerprints”.

An expert, who calculates the peaks of the target compounds with known methods (MestreC, ACD-simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1H-NMR interpretation.

Further details of NMR-data description with peak lists you find in the publication “Citation of NMR Peaklist Data within Patent Applications” of the Research Disclosure Database Number 564025.

Biology

EXAMPLE A In Vivo Preventive Test on Phytophthora Infestans (Tomato Late Blight)

The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween®, and then diluted with water to obtain the desired active material concentration.

The young plants of tomato are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.

After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Phytophthora infestans spores. The contaminated tomato plants are incubated for 5 days at 16-18° C. and at 100% relative humidity.

The test is evaluated 5 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.

In this test the following compounds according to the invention showed efficacy of at least 70% at a concentration of 500 ppm of active ingredient.

Example % efficacy 1 99 2 100 3 99 4 98 7 100 8 100 9 100 10 100 11 100 12 100 15 80 16 78 17 99 18 98 19 90 22 95 23 92

EXAMPLE B In Vivo Preventive Test on Septoria Tritici (Leaf Spot on Wheat)

The tested active ingredients are prepared by homogenization in a mixture of acetone/Dimethyl sulfoxide/tween®, and then diluted with water to obtain the desired active material concentration.

The young plants of wheat are treated by spraying the active ingredient prepared as described above. Control plants are treated only with an aqueous solution of acetone/Dimethyl sulfoxide/tween®.

After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Septoria tritici spores. The contaminated wheat plants are incubated for 72 hours at 18° C. and at 100% relative humidity and then for 21 days at 20° C. and at 90% relative humidity.

The test is evaluated 24 days after the inoculation. 0% means an efficacy which corresponds to that of the control plants while an efficacy of 100% means that no disease is observed.

In this test the following compounds according to the invention showed efficacy of at least 70% at a concentration of 500 ppm of active ingredient.

Example % efficacy 2 71 19 79 22 71 23 97

EXAMPLE C Plasmopara Test (Grapevines)/Preventive

Solvent: 24.5 parts by weight of acetone 24.5 parts by weight of dimethylacetamide Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for preventive activity, young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Plasmopara viticola and then remain for 1 day in an incubation cabinet at approximately 20° C. and a relative atmospheric humidity of 100%. The plant is subsequently placed for 4 days in a greenhouse at approximately 21° C. and a relative atmospheric humidity of approximately 90%. The plants are then misted and placed for 1 day in an incubation cabinet.

The test is evaluated 6 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.

In this test the following compounds according to the invention showed efficacy of 70% or even higher at a concentration of 10 ppm of active ingredient.

Ex-no % efficacy 8 92 10 96 11 100 12 73 Chemistry

The following examples illustrate in a non-limiting manner the preparation and efficacy of the compounds of formula (I) according to the invention.

PREPARATION EXAMPLE 1 N′-hydroxy-N-{6-[({[(Z)-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}ethanimidamide (Compound 1) According to Process P4

Step 1:

To a solution of (2Z)-(hydroxyimino)(phenyl)acetonitrile (2.5 g, 17.10 mmol, 1 eq.) in 100 ml of acetonitrile and 10 ml DMF was added tert-butyl [6-(chloromethyl)pyridin-2-yl]carbamate (4.15 g, 17.10 mmol, 1 eq.) followed by potassium iodide (283 mg, 1.71 mmol, 0.1 eq.) and caesium carbonate (8.36 g, 25.65 mmol, 1.5 eq.). The reaction was stirred overnight at room temperature. The solvent was then evaporated and the residue dissolved in EtOAc (100 ml). The organic layer was washed with H₂O and dried over MgSO₄ then concentrated. tert-butyl {6-[({[(Z)-cyano(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate (5.39 g, 80% yield, only 1 oxime isomer) was obtained as a white solid.

Step 2:

To a solution of tert-butyl {6-[({[(Z)-cyano(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbamate (5.4 g, 15.32 mmol, 1 eq.) in DCM (200 ml) was added TFA (17.47 g, 153 mmol, 10 eq.). The solution was refluxed for 12 h. The reaction was quenched by addition of aq. sat. NaHCO₃ and extracted with EtOAc (3×50 ml). The organics were combined, dried over MgSO₄ and concentrated to give (2Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)acetonitrile (3.86g, 89% yield).

Step 3:

To a suspension of (2Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)acetonitrile (4 g, 15.85 mmol, 1 eq.) in iPrOH/H₂O (10/1, 110 ml) were added hydroxylamine hydrochloride (3.30 g, 47.56 mmol, 3 eq.) and potassium carbonate (6.57 g, 47.56 mmol, 3 eq.). The reaction was heated to 80° C. for 6 h and the solvent was evaporated to ¾^(th). The residue was extracted with EtOAc (3×50 ml) and washed with aq. sat. NaCl. The organics were combined, dried over MgSO₄ and concentrated to give (Z)-2-{[(6-aminopyridin-2-yl)methoxy]imino}-N′-hydroxy-2-phenylethanimidamide (5 g, 99% yield) as a white solid.

Step 4:

To a solution of (1Z,2Z)-2-{[(6-aminopyridin-2-yl)methoxy]imino}-N′-hydroxy-2-phenylethanimidamide (3 g, 10.51 mmol, 1 eq.) in DMF (50 ml) was added CDI (1.70 g, 10.51 mmol, 1 eq.) and stirring at room temperature was allowed for 30 min before heated to 80° C. for 6 h. The reaction was quenched by addition of water and extracted with EtOAc (3×50 ml). The organics were combined, washed with aq. sat. NaCl, dried over MgSO₄ and concentrated. The residue was triturated in MeCN and a white solid was isolated by filtration giving a first crop of 3-[(Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)methyl]-1,2,4-oxadiazol-5(4H)-one (1.36 g, 36% yield). The mother liquor was concentrated and purified by chromatography on silica gel to give a second crop (2.9 g, 50% purity, 40% yield).

Step 5:

To a solution of 3-[(Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)methyl]-1,2,4-oxadiazol-5(4H)-one (1 g, 3.21 mmol, 1 eq.) in MeCN (50 ml) and DMF (10 ml) was added potassium carbonate (532 mg, 3.85 mmol, 1.2 eq.) followed by iodomethane (547 mg, 3.85 mmol, 1.2 eq.). The reaction was stirred at room temperature overnight. The reaction was quenched by addition of water and extracted with EtOAc (3×50 ml). The organics were combined, washed with aq. sat. NaCl, dried over MgSO₄ and concentrated. The residue was purified by chromatography on silica gel to give 3-[(Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)methyl]-4-methyl-1,2,4-oxadiazol-5(4H)-one (906 mg, 85% yield) has a white solid.

Step 6:

To a solution of 3-[(Z)-{[(6-aminopyridin-2-yl)methoxy]imino}(phenyl)methyl]-4-methyl-1,2,4-oxadiazol-5(4H)-one (600 mg, 1.84 mol, 1 eq) in isopropanol (8 mL) was added N,N-dimethylacetamide dimethyl acetal. The mixture was refluxed for 4 h30. Hydroxylamine hydrochloride (154 mg, 2.21 mmol, 1.2 eq) was added at room temperature and the mixture was stirred at room temperature for 2 days. The solvent was then evaporated and water was added. The resulting precipitate was filtered and dried under vacuum to afford N′-hydroxy-N-{6-[({[(Z)-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}ethanimidamide (660 mg, 75% yield) as a white solid.

PREPARATION EXAMPLE 2 N′-(cyclopropylmethoxy)-N-{6-[({[(Z)-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}ethanimidamide (Compound 2) According to Process P5

A solution of N′-hydroxy-N-{6-[({[(Z)-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}ethanimidamide (150 mg, 0.392 mmol, 1 eq), iodomethylcyclopropane (0.069 ml, 0.588 mmol, 1.5 eq) and cesium carbonate (191 mg, 0.588 mmol, 1.5 eq) in DMF (3 ml) was stirred at 80° C. for 7 h and overnight at room temperature. Iodomethylcyclopropane (0.069 ml, 0.588 mmol, 1.5 eq), cesium carbonate (191 mg, 0.588 mmol, 1.5 eq) and potassium iodide (0.1 eq) were then added and the mixture was stirred at 60° C. for 8 h. Water was added and the mixture was extracted with ethyl acetate. The organics were combined, dried over MgSO₄ and evaporated. The residue was purified by chromatography on silica gel to afford N′-(cyclopropylmethoxy)-N-{6-[({[(Z)-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}ethanimidamide (20 mg, 10% yield) as a transparent oil.

PREPARATION EXAMPLE 3 2-methyl-3-[(Z)-phenyl({[6-(phenylethynyl)pyridin-2-yl]methoxy}imino)methyl]-1,2,4-oxadiazol-5(2H)-one (Compound 4) According to Process P3

Step 1:

To a solution of (2Z)-(hydroxyimino)(phenyl)acetonitrile (6.0 g, 41.1 mmol, 1 eq.) in 80 ml of acetonitrile and 10 ml of DMF, was added 2-bromo-6-(bromomethyl)pyridine (10.3 g, 41.1 mmol, 1.0 eq.) followed by potassium iodide (681 mg, 4.11 mmol, 0.1 eq.) and caesium carbonate (20.1 g, 61.1 mmol, 1.5 eq.). The reaction was stirred 4 h at room temperature. The solvent was then evaporated and the residue dissolved in EtOAc, subsequently washed with H₂O and brine. After separation, the organic phase was dried over MgSO4 and concentrated. The residue was purified by chromatography on silica gel to give (2Z)-{[(6-bromopyridin-2-yl)methoxy]imino}(phenyl)acetonitrile (11.3 g, 86% yield) as a white solid.

Step 2:

To a solution of (2Z)-{[(6-bromopyridin-2-yl)methoxy]imino}(phenyl)acetonitrile (5.0 g, 15.8 mmol, 1 eq.) in 2-propanol/water (100 ml/10 ml), was added potassium carbonate (4.37 g, 31.6 mmol, 2 eq) and N-methylhydroxylamine hydrochloride (2.64 g, 31.6 mmol, 2 eq). The reaction was heated under stirring to 80° C. for 2 h. The reaction mixture was poured onto water (250 mL) and extracted twice with ethyl acetate (250 mL). The combined organic layers were washed with brine, dried over MgSO4 and concentrated to give (2Z)-2-{[(6-bromopyridin-2-yl)methoxy]imino}-N-hydroxy-N-methyl-2-phenylethanimidamide (5.3 g, 90% yield), as a yellow solid which was used in the next step without further purification.

Step 3:

To a solution of (2Z)-2-{[(6-bromopyridin-2-yl)methoxy]imino}-N-hydroxy-N-methyl-2-phenylethanimidamide (4.0 g, 11 mmol, 1 eq.) in acetonitrile (100 ml), was added 1,1′-carbonyldiimidazole (2.14 g, 13.2 mmol, 1.2 eq.). After stirring at 80° C. for 1 hours and 2 hours at room temperature, the reaction was diluted with EtOAc (500 mL), subsequently washed with H₂O (500 mL) and brine. After separation, the organic phase was dried over MgSO₄ then concentrated. The residue was purified by chromatography on silica gel to give 3-[(Z)-{[(6-bromopyridin-2-yl)methoxy]imino}(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (4.40 g, 95% yield).

Step 4:

To a solution of 3-[(Z)-{[(6-bromopyridin-2-yl)methoxy]imino}(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (200 mg, 0.514 mmol, 1 eq) in degased THF (2 mL) was added in a microwave tube under argon tetrakis(triphenylphosphine)palladium (0) (59.4 mg, 0.051 mmol, 0.1 eq), copper iodide (14.6 mg, 0.077 mmol, 0.15 eq) N,N-diisopropylethylamine (0.358 ml, 2.06 mmol, 4 eq) and phenylacetylene (157 mg, 1.54 mmol, 3 eq). The mixture was heated in the microwave at 120° C. for 15 min. The mixture was concentrated, diluted with ethyl acetate and filtered over a celite cartridge. The solvent was evaporated and the residue was purified by chromatography on silica gel to afford 2-methyl-3-[(Z)-phenyl({[6-(phenylethynyl)pyridin-2-yl]methoxy}imino)methyl]-1,2,4-oxadiazol-5(2H)-one (115 mg, 52% yield).

PREPARATION EXAMPLE 4 3-[(Z)-({[2-(cyclopropylethynyl)-1,3-thiazol-4-yl]methoxy}imino)(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (Compound 12) According to Process P3

Step 1:

To a mixture of (2Z)-(hydroxyimino)(phenyl)acetonitrile (2.9 g, 19.84 mmol, 1 eq.), 2-bromo-4-(bromomethyl)thiazole (5.10 g, 19.84 mmol, 1 eq.), potassium iodide (329 mg, 1.98 mmol, 0.1 eq.) and caesium carbonate (9.70 g, 29.76 mmol, 1.5 eq.) was added 80 ml of acetonitrile and 10 ml of DMF. The reaction was stirred 2 h at room temperature. The solvent was then evaporated and the residue dissolved in EtOAc, subsequently washed with H₂O and brine. After separation, the organic phase was dried over MgSO₄ then concentrated. The residue was purified by chromatography on silica gel to give (2Z)-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}(phenyl)acetonitrile (5.70 g, 88% yield, only 1 oxime isomer).

Step 2:

To a solution of (2Z)-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}(phenyl)acetonitrile (2.50 g, 7.76 mmol, 1 eq.) and potassium carbonate (2.14 g, 15.52 mmol, 2.0 eq) in 2-propanol/water (40 ml/10 ml), was added N-methylhydroxylamine hydrochloride (1.30 g, 15.52 mmol, 2 eq.). The reaction was heated under stirring to 80° C. for 2 h and the solvent was evaporated to ¾^(th). The residue was extracted with EtOAc and washed with water. The organics were combined, dried over MgSO₄ and concentrated to give (2Z)-2-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}-N-hydroxy-N-methyl-2-phenylethanimidamide (2.30 g, 78% yield), as a yellow solid.

Step 3:

To a solution of (2Z)-2-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}-N-hydroxy-N-methyl-2-phenylethanimidamide (1.8 g, 4.87 mmol, 1 eq.) in acetonitrile (120 ml), was added 1,1′-carbonyldiimidazole (1.58 g, 9.75 mmol, 2 eq.). After stirring at 80° C. for 1 hour, the reaction was quenched by addition of water (100 ml) and extracted with EtOAc (2×100 ml). The organics were combined, dried over MgSO₄ and concentrated. The residue was purified by chromatography on silica gel to give 3-[(Z)-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (2 g, 100% yield).

Step 4:

To a solution of 3-[(Z)-{[(2-bromo-1,3-thiazol-4-yl)methoxy]imino}(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (210 mg, 0.514 mmol, 1 eq) in degased THF (2 mL) was added in a microwave tube under argon tetrakis(triphenylphosphine)palladium (0) (59.4 mg, 0.051 mmol, 0.1 eq), copper iodide (14.6 mg, 0.077 mmol, 0.15 eq) N,N-diisopropylethylamine (0.358 ml, 2.06 mmol, 4 eq) and phenylacetylene (157 mg, 1.54 mmol, 3 eq). The mixture was stirred at room temperature for 2 days. The mixture was concentrated, diluted with ethyl acetate and filtered over a celite cartridge. The solvent was evaporated and the residue was purified by chromatography on silica gel to afford 3-[(Z)-({[2-(cyclopropylethynyl)-1,3-thiazol-4-yl]methoxy}imino)(phenyl)methyl]-2-methyl-1,2,4-oxadiazol-5(2H)-one (148 mg, 73% yield). 

The invention claimed is:
 1. A compound of formula (I)

wherein X¹ represents a hydrogen atom, a formyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, a substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted C₁-C₈-alkylcarbonyl; X² and X³ independently represents O or C═O, provided that X² represents O when X³ is C═O and X² represents C═O when X³ is O A is selected in the list consisting of A¹ to A²:

wherein Z¹ represents a sulfenyl group, a formyl group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a formyloxy group, a carbamoyl group, a N-hydroxycarbamoyl group, sulfenylthioylamino, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted (C₁-C₈-alkylamino)-amino group, substituted or non-substituted N—C₁-C₈-alkyl-(C₁-C₈-alkylamino)-amino group, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted aryl-C₂-C₈-alkynyl, substituted or non-substituted C₃-C₈-cycloalkyl-C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted C₁-C₈-alkylcarbonyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N,N′-di-C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbamoyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N,N′-di-C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N,N′-di-C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamothioyl, substituted or non-substituted C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted (C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted substituted or non-substituted (di-C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₁-C₈-halogenoalkylsulfenyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted C₁-C₈-alkylaminosulfamoyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted C₁-C₈-alkylsulfenylamino, substituted or non-substituted C₁-C₈-alkylsulfonylamino, substituted or non-substituted C₁-C₈-alkoxysulfonylamino, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted (C₁-C₆-alkylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkenylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkynylideneamino)oxy, substituted or non-substituted (benzylideneamino)oxy, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino; Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted C₁-C₈-alkoxy; Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, a nitro group, a cyano group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, a C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₁-C₈-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-halogenoalkanimidoyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted heterocyclyl, or substituted or non-substituted heterocyclyloxy; wherein said compound can comprise a salt, N-oxide, metallic complex and/or metalloidic complex thereof and/or an (E) and/or (Z) isomer and/or a mixture thereof.
 2. A compound according to claim 1 wherein X¹ represents a hydrogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl or a substituted or non-substituted C₂-C₈-alkenyl.
 3. A compound according to claim 2 wherein X¹ represents a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, an isopropyl group or a cyclopropyl group.
 4. A compound according to claim 1 wherein Z¹ represents a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino.
 5. A compound according to claim 4 wherein Z¹ represents substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino.
 6. A compound according to claim 5 wherein Z¹ represents substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino.
 7. A compound according to claim 1 wherein Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen atom, or substituted or non-substituted C₁-C₈-alkyl.
 8. A compound according to claim 1 wherein Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, or substituted or non-substituted C₁-C₈-alkoxy.
 9. A compound according to claim 8 wherein Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, methyl, ethyl, isopropyl, isobutyl, tertbutyl, trifluoromethyl, difluoromethyl, allyl, ethynyl, propargyl, cyclopropyl, methoxy or trifluoromethoxy.
 10. The compound of claim 1, wherein A is A¹.
 11. The compound of claim 1, wherein A is A².
 12. A compound of formula (V)

wherein A is selected in the list consisting of A¹ to A²:

wherein Z¹ represents a sulfenyl group, a formyl group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a formyloxy group, a carbamoyl group, a N-hydroxycarbamoyl group, sulfenylthioylamino, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted (C₁-C₈-alkylamino)-amino group, substituted or non-substituted N—C₁-C₈-alkyl-(C₁-C₈-alkylamino)-amino group, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted aryl-C₂-C₈-alkynyl, substituted or non-substituted C₃-C₈-cycloalkyl-C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted C₁-C₈-alkylcarbonyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N,N′-di-C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbamoyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N,N′-di-C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N,N′-di-C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamothioyl, substituted or non-substituted C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted (C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted substituted or non-substituted (di-C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₁-C₈-halogenoalkylsulfenyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted C₁-C₈-alkylaminosulfamoyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted C₁-C₈-alkylsulfenylamino, substituted or non-substituted C₁-C₈-alkylsulfonylamino, substituted or non-substituted C₁-C₈-alkoxysulfonylamino, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted (C₁-C₆-alkylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkenylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkynylideneamino)oxy, substituted or non-substituted (benzylideneamino)oxy, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino; Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted C₁-C₈-alkoxy; Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, a nitro group, a cyano group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, a C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₁-C₈-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-halogenoalkanimidoyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted heterocyclyl, or substituted or non-substituted heterocyclyloxy; wherein said compound can comprise a salt, N-oxide, metallic complex and/or metalloidic complex thereof and/or (E) and/or (Z) isomer and/or mixture thereof.
 13. The compound of claim 12, wherein A is A¹.
 14. The compound of claim 12, wherein A is A².
 15. A compound of formula (VI)

wherein X¹ represents a hydrogen atom, a formyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, a substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted C₁-C₈-alkylcarbonyl; A is selected in the list consisting of A¹ to A²:

wherein Z¹ represents a sulfenyl group, a formyl group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a formyloxy group, a carbamoyl group, a N-hydroxycarbamoyl group, sulfenylthioylamino, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted (C₁-C₈-alkylamino)-amino group, substituted or non-substituted N—C₁-C₈-alkyl-(C₁-C₈-alkylamino)-amino group, a substituted or non-substituted (hydroxyimino)-C₁-C₆-alkyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted aryl-C₂-C₈-alkynyl, substituted or non-substituted C₃-C₈-cycloalkyl-C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted C₁-C₈-alkylcarbonyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N,N′-di-C₁-C₈-alkyl-carbamoyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbamoyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamoyl, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N,N′-di-C₁-C₈-alkylaminocarbonyloxy, substituted or non-substituted N—C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N,N′-di-C₁-C₈-alkylcarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyloxycarbamothioyl, substituted or non-substituted C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted N—C₁-C₈-alkyl-C₁-C₈-alkoxycarbamothioyl, substituted or non-substituted (C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted substituted or non-substituted (di-C₁-C₈-alkyl-carbamothioyl)-oxy, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₁-C₈-halogenoalkylsulfenyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted C₁-C₈-alkylaminosulfamoyl, substituted or non-substituted (C₁-C₆-alkoxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkenyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (C₁-C₆-alkynyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted (benzyloxyimino)-C₁-C₆-alkyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted C₁-C₈-alkylsulfenylamino, substituted or non-substituted C₁-C₈-alkylsulfonylamino, substituted or non-substituted C₁-C₈-alkoxysulfonylamino, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted (C₁-C₆-alkylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkenylideneamino)oxy, substituted or non-substituted (C₁-C₆-alkynylideneamino)oxy, substituted or non-substituted (benzylideneamino)oxy, substituted or non-substituted (N-hydroxy-C₁-C₆-alkanimidoyl)amino, or substituted or non-substituted (N—C₁-C₆-alkoxy-C₁-C₆-alkanimidoyl)amino; Z², Z³ and Z⁴ independently represent a hydrogen atom, a halogen atom, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, or substituted or non-substituted C₁-C₈-alkoxy; Y¹ to Y⁵ independently represent a hydrogen atom, a halogen atom, a nitro group, a cyano group, a substituted or non-substituted carbaldehyde O—(C₁-C₈-alkyl)oxime, a pentafluoro-λ⁶-sulfenyl group, substituted or non-substituted C₁-C₈-alkyl, substituted or non-substituted C₃-C₈-cycloalkyl, substituted or non-substituted C₁-C₈-halogenoalkyl having 1 to 5 halogen atoms, a C₂-C₈-alkenyl, substituted or non-substituted C₂-C₈-alkynyl, substituted or non-substituted C₁-C₈-alkoxy, substituted or non-substituted C₁-C₈-halogenoalkoxy having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkylsulfenyl, substituted or non-substituted C₂-C₈-alkenyloxy, substituted or non-substituted C₃-C₈-alkynyloxy, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-alkanimidoyl, substituted or non-substituted N—(C₁-C₈-alkoxy)-C₁-C₈-halogenoalkanimidoyl having 1 to 5 halogen atoms, substituted or non-substituted C₁-C₈-alkoxycarbonyl, substituted or non-substituted C₁-C₈-alkylcarbonyloxy, substituted or non-substituted C₁-C₈-alkylsulfinyl, substituted or non-substituted C₁-C₈-alkylsulfonyl, substituted or non-substituted phenoxy, substituted or non-substituted phenylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted tri(C₁-C₈-alkyl)-silyloxy, substituted or non-substituted tri(C₁-C₈-alkyl)-silyl, substituted or non-substituted heterocyclyl, or substituted or non-substituted heterocyclyloxy; wherein said compound can comprise a salt, N-oxide, metallic complex and/or metalloidic complex thereof and/or an (E) and/or (Z) isomer and/or mixture thereof.
 16. The compound of claim 15, wherein A is A¹.
 17. The compound of claim 15, wherein A is A².
 18. A fungicide composition comprising, as an active ingredient, an effective amount of a compound according to claim 1 and an agriculturally acceptable support, carrier and/or filler.
 19. A method for controlling phytopathogenic fungi of crops, comprising applying an agronomically effective and substantially non-phytotoxic quantity of a compound according to claim 1 to soil where one or more plants grow or are capable of growing, to leaves and/or fruit of plants and/or to seed of one or more plants.
 20. A process for producing a composition for controlling phytopathogenic harmful fungi, comprising mixing a compound according to claim 1 with one or more extenders and/or surfactants. 